

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use INVEGA® SUSTENNA® safely and effectively. See full prescribing information for INVEGA® SUSTENNA®.

INVEGA® SUSTENNA® (paliperidone palmitate) extended-release injectable suspension, for intramuscular use  
Initial U.S. Approval: 2006

### WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

See full prescribing information for complete boxed warning.

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. (5.1)
- INVEGA® SUSTENNA® is not approved for use in patients with dementia-related psychosis. (5.1)

### RECENT MAJOR CHANGES

Indications and Usage (1) 11/2014  
Dosage and Administration (2.2, 2.3) 11/2014

### INDICATIONS AND USAGE

INVEGA® SUSTENNA® is an atypical antipsychotic indicated for

- Treatment of schizophrenia. (1)
- Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants. (1)

### DOSAGE AND ADMINISTRATION

- For intramuscular injection only. (2.1)
- Each injection must be administered only by a health care professional. (2.1)
- For deltoid injection, use 1-inch 23G needle for patients weighing less than 90 kg or 1½-inch 22G needle for patients weighing 90 kg or more. For gluteal injection, use 1½-inch 22G needle regardless of patient weight. (2.1)

| Indication                     | Initiation Dosing (deltoid) |        | Monthly Maintenance Dose <sup>a</sup> (deltoid or gluteal) | Maximum Monthly Dose |
|--------------------------------|-----------------------------|--------|------------------------------------------------------------|----------------------|
|                                | Day 1                       | Day 8  |                                                            |                      |
| Schizophrenia (2.2)            | 234 mg                      | 156 mg | 39-234 mg <sup>b</sup>                                     | 234 mg               |
| Schizoaffective disorder (2.2) | 234 mg                      | 156 mg | 78-234 mg <sup>c</sup>                                     | 234 mg               |

<sup>a</sup> Administered 5 weeks after the first injection.

<sup>b</sup> The recommended maintenance dose for treatment of schizophrenia is 117 mg. Some patients may benefit from lower or higher maintenance doses within the additional available strengths (39 mg, 78 mg, 156 mg, and 234 mg).

<sup>c</sup> Adjust dose based on tolerability and/or efficacy using available strengths. The 39 mg strength was not studied in the long-term schizoaffective disorder study.

- For patients naïve to oral paliperidone or oral or injectable risperidone, establish tolerability with oral paliperidone or oral risperidone prior to initiating treatment with INVEGA® SUSTENNA®. (2.2)
- Missed Doses: To manage either a missed second initiation dose or a missed monthly maintenance dose, refer to the Full Prescribing Information. (2.3)
- Moderate to severe renal impairment (creatinine clearance < 50 mL/min): INVEGA® SUSTENNA® is not recommended. (2.5)
- Mild renal impairment (creatinine clearance ≥ 50 mL/min to < 80 mL/min): Administer 156 mg on treatment day 1 and 117 mg one week later, both administered in the deltoid muscle. Follow with monthly injections of 78 mg in either the deltoid or gluteal muscle. (2.5)

### DOSAGE FORMS AND STRENGTHS

Extended-release injectable suspension: 39 mg, 78 mg, 117 mg, 156 mg, or 234 mg (3)

### CONTRAINDICATIONS

Known hypersensitivity to paliperidone, risperidone, or to any excipients in the formulation (4)

### WARNINGS AND PRECAUTIONS

- **Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis:** Increased incidence of cerebrovascular adverse reactions (e.g. stroke, transient ischemic attack, including fatalities). INVEGA® SUSTENNA® is not approved for use in patients with dementia-related psychosis (5.2)
- **Neuroleptic Malignant Syndrome:** Manage with immediate discontinuation of drug and close monitoring (5.3)
- **QT Prolongation:** Avoid use with drugs that also increase QT interval and in patients with risk factors for prolonged QT interval (5.4)
- **Tardive Dyskinesia:** Discontinue drug if clinically appropriate (5.5)
- **Metabolic Changes:** Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include:
  - **Hyperglycemia and Diabetes Mellitus:** Monitor for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes. (5.6)
  - **Dyslipidemia:** Undesirable alterations have been observed. (5.6)
  - **Weight Gain:** Significant weight gain has been reported. Monitor weight gain. (5.6)
- **Orthostatic Hypotension and Syncope:** Use with caution in patients with known cardiovascular or cerebrovascular disease and patients predisposed to hypotension (5.7)
- **Leukopenia, Neutropenia, and Agranulocytosis:** Monitor complete blood count in patients with a history of a clinically significant low white blood cell count (WBC) or a drug-induced leukopenia/neutropenia. Consider discontinuation if clinically significant decline in WBC in the absence of other causative factors (5.8)
- **Hyperprolactinemia:** Prolactin elevations occur and persist during chronic administration (5.9)
- **Potential for Cognitive and Motor Impairment:** Use caution when operating machinery (5.10)
- **Seizures:** Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold (5.11)

### ADVERSE REACTIONS

The most common adverse reactions (incidence ≥ 5% and occurring at least twice as often as placebo) were injection site reactions, somnolence/sedation, dizziness, akathisia, and extrapyramidal disorder. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch)

### DRUG INTERACTIONS

- Drugs that may cause orthostatic hypotension: An additive effect may occur when co-administered with INVEGA® SUSTENNA®. (7.1)
- Strong CYP3A4/P-glycoprotein (P-gp) inducers: It may be necessary to increase the dose of INVEGA® SUSTENNA® when a strong inducer of both CYP3A4 and P-gp (e.g., carbamazepine, rifampin, St John's wort) is co-administered. Conversely, on discontinuation of the strong inducer, it may be necessary to decrease the dose of INVEGA® SUSTENNA®. (7.2, 12.3)

### USE IN SPECIFIC POPULATIONS

- **Pregnancy:** Based on animal data, may cause fetal harm. (8.1)
  - **Nursing Mothers:** Discontinue drug or nursing, taking into consideration the importance of drug to the mother. (8.3)
- See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 11/2014

## FULL PRESCRIBING INFORMATION: CONTENTS\*

### WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

#### 1 INDICATIONS AND USAGE

#### 2 DOSAGE AND ADMINISTRATION

- 2.1 Administration Instructions
- 2.2 Schizophrenia and Schizoaffective Disorder
- 2.3 Missed Doses
- 2.4 Use with Oral Paliperidone or with Risperidone
- 2.5 Dosage Adjustments
- 2.6 Switching from Other Antipsychotics
- 2.7 Instructions for Use

#### 3 DOSAGE FORMS AND STRENGTHS

#### 4 CONTRAINDICATIONS

#### 5 WARNINGS AND PRECAUTIONS

- 5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis
- 5.2 Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis
- 5.3 Neuroleptic Malignant Syndrome
- 5.4 QT Prolongation
- 5.5 Tardive Dyskinesia
- 5.6 Metabolic Changes
- 5.7 Orthostatic Hypotension and Syncope
- 5.8 Leukopenia, Neutropenia, and Agranulocytosis
- 5.9 Hyperprolactinemia
- 5.10 Potential for Cognitive and Motor Impairment
- 5.11 Seizures
- 5.12 Dysphagia
- 5.13 Priapism
- 5.14 Disruption of Body Temperature Regulation

#### 6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience
- 6.3 Adverse Reactions Reported With Risperidone

#### 7 DRUG INTERACTIONS

- 7.1 Potential for INVEGA® SUSTENNA® to Affect Other Drugs
- 7.2 Potential for Other Drugs to Affect INVEGA® SUSTENNA®

#### 8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Labor and Delivery
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment
- 8.7 Hepatic Impairment
- 8.8 Patients with Parkinson's Disease or Lewy Body Dementia

#### 9 DRUG ABUSE AND DEPENDENCE

- 9.1 Controlled Substance
- 9.2 Abuse
- 9.3 Dependence

#### 10 OVERDOSAGE

- 10.1 Human Experience
- 10.2 Management of Overdosage

#### 11 DESCRIPTION

#### 12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

#### 13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

#### 14 CLINICAL STUDIES

- 14.1 Schizophrenia
- 14.2 Schizoaffective Disorder

#### 16 HOW SUPPLIED/STORAGE AND HANDLING

#### 17 PATIENT COUNSELING INFORMATION PATIENT INFORMATION

\*Sections or subsections omitted from the full prescribing information are not listed

## FULL PRESCRIBING INFORMATION

### WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

- **Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death [see Warnings and Precautions (5.1)].**
- **INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> is not approved for use in patients with dementia-related psychosis [see Warnings and Precautions (5.1)].**

## 1 INDICATIONS AND USAGE

INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> (paliperidone palmitate) is indicated for the treatment of:

- Schizophrenia [see Clinical Studies 14.1].
- Schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants [see Clinical Studies 14.2].

## 2 DOSAGE AND ADMINISTRATION

### 2.1 Administration Instructions

Each injection must be administered only by a health care professional.

Parenteral drug products should be inspected visually for foreign matter and discoloration prior to administration, whenever product and container permit.

INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> is intended for intramuscular use only. Do not administer by any other route. Avoid inadvertent injection into a blood vessel. Administer the dose in a single injection; do not administer the dose in divided injections. Inject slowly, deep into the muscle.

The recommended needle size for administration of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> into the deltoid muscle is determined by the patient's weight:

- For patients weighing less than 90 kg, the 1-inch, 23 gauge needle is recommended.
- For patients weighing 90 kg or more, the 1½-inch, 22 gauge needle is recommended.

Deltoid injections should be alternated between the two deltoid muscles.

The recommended needle size for administration of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> into the gluteal muscle is the 1½-inch, 22 gauge needle regardless of patient weight.

Administer into the upper-outer quadrant of the gluteal muscle. Gluteal injections should be alternated between the two gluteal muscles.

## 2.2 Schizophrenia and Schizoaffective Disorder

For patients who have never taken oral paliperidone or oral or injectable risperidone, it is recommended to establish tolerability with oral paliperidone or oral risperidone prior to initiating treatment with INVEGA® SUSTENNA®.

The recommended dosing of INVEGA® SUSTENNA® for each approved indication is displayed in Table 1. The recommended initiation of INVEGA® SUSTENNA® is with a dose of 234 mg on treatment day 1 and 156 mg one week later, both administered in the deltoid muscle. Following the second initiation dose, monthly maintenance doses can be administered in either the deltoid or gluteal muscle.

**Table 1. Recommended Dosing of INVEGA® SUSTENNA® for Adults with Schizophrenia or Schizoaffective Disorder**

| Indication               | Initiation Dosing (deltoid) |        | Monthly Maintenance Dose <sup>a</sup> (deltoid or gluteal) | Maximum Monthly Dose |
|--------------------------|-----------------------------|--------|------------------------------------------------------------|----------------------|
|                          | Day 1                       | Day 8  |                                                            |                      |
| Schizophrenia            | 234 mg                      | 156 mg | 39-234 mg <sup>b</sup>                                     | 234 mg               |
| Schizoaffective disorder | 234 mg                      | 156 mg | 78-234 mg <sup>c</sup>                                     | 234 mg               |

<sup>a</sup> Administered 5 weeks after the first injection.

<sup>b</sup> The recommended maintenance dose for treatment of schizophrenia is 117 mg. Some patients may benefit from lower or higher maintenance doses within the additional available strengths (39 mg, 78 mg, 156 mg, and 234 mg).

<sup>c</sup> Adjust dose based on tolerability and/or efficacy using available strengths. The 39 mg strength was not studied in the long-term schizoaffective disorder study.

Adjustment of the maintenance dose may be made monthly. When making dose adjustments, the prolonged-release characteristics of INVEGA® SUSTENNA® should be considered [*see Clinical Pharmacology (12.3)*], as the full effect of the dose adjustment may not be evident for several months.

## 2.3 Missed Doses

### Avoiding Missed Doses

It is recommended that the second initiation dose of INVEGA® SUSTENNA® be given one week after the first dose. To avoid a missed dose, patients may be given the second dose 4 days before or after the one-week time point. Similarly, the third and subsequent injections after the initiation regimen are recommended to be given monthly. To avoid a missed monthly dose, patients may be given the injection up to 7 days before or after the monthly time point.

### **Management of a Missed Second Initiation Dose**

If the target date for the second INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> injection (one week  $\pm$  4 days) is missed, the recommended reinitiation depends on the length of time which has elapsed since the patient's first injection. In case of a missed second initiation dose follow the dosing instructions provided in Table 2.

**Table 2. Management of a Missed Second Initiation Dose**

| <b>TIMING OF MISSED SECOND INITIATION DOSE</b> | <b>DOSING</b>                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Less than 4 weeks since first injection</b> | <b>Administer the second initiation dose of 156 mg in the deltoid muscle as soon as possible.</b><br><ol style="list-style-type: none"><li>1. It is recommended to administer a third injection of 117 mg in either the deltoid or gluteal muscle 5 weeks after the first injection (regardless of the timing of the second injection).</li><li>2. Thereafter, resume regular monthly dosing in either the deltoid or gluteal muscle.</li></ol> |
| <b>4 to 7 weeks since first injection</b>      | <b>Resume dosing with two injections of 156 mg in the following manner:</b><br><ol style="list-style-type: none"><li>1. Administer a deltoid injection as soon as possible.</li><li>2. Administer a second deltoid injection 1 week later.</li><li>3. Thereafter, resume regular monthly dosing in either the deltoid or gluteal muscle.</li></ol>                                                                                              |
| <b>More than 7 weeks since first injection</b> | <b>Restart dosing with recommended initiation (see Section 2.2, Table 1):</b><br><ol style="list-style-type: none"><li>1. Administer a 234 mg deltoid injection on Day 1.</li><li>2. Administer a 156 mg deltoid injection 1 week later.</li><li>3. Thereafter, resume regular monthly dosing in either the deltoid or gluteal muscle.</li></ol>                                                                                                |

### **Management of a Missed Maintenance Dose**

In case of a missed maintenance dose follow the dosing instructions provided in Table 3.

**Table 3. Management of a Missed Maintenance Dose**

| <b>TIMING OF MISSED MAINTENANCE DOSE</b>                  | <b>DOSING</b>                                                                                                                                                                                                                                                                                                      |
|-----------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>4 to 6 weeks since last injection</b>                  | <b>Resume regular monthly dosing as soon as possible at the patient's previously stabilized dose, followed by injections at monthly intervals.</b>                                                                                                                                                                 |
| <b>More than 6 weeks to 6 months since last injection</b> | <b>Resume the same dose the patient was previously stabilized on (unless the patient was stabilized on a dose of 234 mg, then the first 2 injections should each be 156 mg) in the following manner:</b><br><ol style="list-style-type: none"><li>1. Administer a deltoid injection as soon as possible.</li></ol> |

|                                                |                                                                                                                                                                                                                                                                                                                                                                                                                   |
|------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                | <ol style="list-style-type: none"> <li>2. Administer a second deltoid injection 1 week later at the same dose.</li> <li>3. Thereafter, resume administering the previously stabilized dose in the deltoid or gluteal muscle 1 month after the second injection.</li> </ol>                                                                                                                                        |
| <b>More than 6 months since last injection</b> | <p><b>Restart dosing with recommended initiation</b> (<i>see Section 2.2, Table 1</i>):</p> <ol style="list-style-type: none"> <li>1. Administer a 234 mg deltoid injection on Day 1.</li> <li>2. Administer a 156 mg deltoid injection 1 week later.</li> <li>3. Thereafter, resume administering the previously stabilized dose in the deltoid or gluteal muscle 1 month after the second injection.</li> </ol> |

## 2.4 Use with Oral Paliperidone or with Risperidone

Concomitant use of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> with oral paliperidone or oral or injectable risperidone has not been studied. Since paliperidone is the major active metabolite of risperidone, consideration should be given to the additive paliperidone exposure if any of these medications are coadministered with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>.

## 2.5 Dosage Adjustments

### Renal Impairment

INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> has not been systematically studied in patients with renal impairment [*see Clinical Pharmacology (12.3)*]. For patients with mild renal impairment (creatinine clearance  $\geq 50$  mL/min to  $< 80$  mL/min [Cockcroft-Gault Formula]), initiate INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> with a dose of 156 mg on treatment day 1 and 117 mg one week later. Administer both doses in the deltoid muscle. Thereafter, follow with monthly injections of 78 mg in either the deltoid or gluteal muscle [*see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)*].

INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> is not recommended in patients with moderate or severe renal impairment (creatinine clearance  $< 50$  mL/min) [*see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)*].

### Coadministration with Strong CYP3A4/P-glycoprotein (P-gp) Inducers

It may be necessary to increase the dose of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> when a strong inducer of both CYP3A4 and P-gp (e.g., carbamazepine, rifampin, St John's wort) is co-administered. Conversely, on discontinuation of the strong inducer, it may be necessary to decrease the dose of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> [*see Drug Interactions (7.2) and Clinical Pharmacology (12.3)*].

## 2.6 Switching from Other Antipsychotics

There are no systematically collected data to specifically address switching patients with schizophrenia or schizoaffective disorder from other antipsychotics to INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>, or concerning concomitant administration with other antipsychotics.

### 2.6.1 Switching from Oral Antipsychotics

For patients who have never taken oral paliperidone or oral or injectable risperidone, tolerability should be established with oral paliperidone or oral risperidone prior to initiating treatment with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>.

Previous oral antipsychotics can be discontinued at the time of initiation of treatment with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>. Recommended initiation of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> is with a dose of 234 mg on treatment day 1 and 156 mg one week later, both administered in the deltoid muscle [see *Dosage and Administration (2.2)*]. Patients previously stabilized on different doses of INVEGA<sup>®</sup> Extended-Release tablets can attain similar paliperidone steady-state exposure during maintenance treatment with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> monthly doses as depicted in Table 4.

**Table 4. Doses of INVEGA<sup>®</sup> and INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> needed to attain similar steady-state paliperidone exposure during maintenance treatment**

| Formulation      | INVEGA <sup>®</sup><br>Extended-Release Tablet | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup><br>Injection |
|------------------|------------------------------------------------|--------------------------------------------------------|
| Dosing Frequency | Once Daily                                     | Once every 4 weeks                                     |
| Dose (mg)        | 12<br>6<br>3                                   | 234<br>117<br>39-78                                    |

### 2.6.2 Switching from Long-Acting Injectable Antipsychotics

For patients who have never taken oral paliperidone or oral or injectable risperidone, tolerability should be established with oral paliperidone or oral risperidone prior to initiating treatment with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>.


When switching patients currently at steady-state on a long-acting injectable antipsychotic, initiate INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> therapy in place of the next scheduled injection. INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> should then be continued at monthly intervals. The one-week initiation dosing regimen as described in Section 2.2 is not required. See Table 1 above for recommended monthly maintenance dosing. Based on previous clinical history of tolerability and/or efficacy, some patients may benefit from lower or higher maintenance doses within the available strengths (39 mg, 78 mg, 117 mg, 156 mg, and 234 mg). The 39 mg strength was not studied in the long-term schizoaffective disorder study. Monthly maintenance doses can be administered in either the deltoid or gluteal muscle [see *Dosage and Administration (2.2)*].

If INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> is discontinued, its prolonged-release characteristics must be considered. As recommended with other antipsychotic medications, the need for continuing existing extrapyramidal symptoms (EPS) medication should be re-evaluated periodically.

## 2.7 Instructions for Use


Each injection must be administered only by a health care professional.

The kit contains a prefilled syringe and 2 safety needles (a 1 ½-inch 22 gauge needle and a 1-inch 23 gauge needle) for intramuscular injection.



INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> is for single use only.

- Shake the syringe vigorously for a minimum of 10 seconds to ensure a homogeneous suspension.



- b. Select the appropriate needle.


For DELTOID injection:

- If the patient weighs less than 90 kg, use the 1-inch **23** gauge needle (needle with **blue** colored hub).
- If the patient weighs 90 kg or more, use the 1 ½-inch **22** gauge needle (needle with **gray** colored hub).


For GLUTEAL injection:

Use the 1 ½-inch **22** gauge needle (needle with **gray** colored hub) regardless of patient's weight.


- c. While holding the syringe upright, remove the rubber tip cap with an easy clockwise twisting motion.




- d. Peel the safety needle pouch half way open. Grasp the needle sheath using the plastic peel pouch. Attach the safety needle to the luer connection of the syringe with an easy clockwise twisting motion.



- e. Pull the needle sheath away from the needle with a straight pull. Do not twist the sheath as the needle may be loosened from the syringe.




- f. Bring the syringe with the attached needle in upright position to de-aerate. De-aerate the syringe by moving the plunger rod carefully forward.




- g. Inject the entire contents intramuscularly slowly, deep into the selected deltoid or gluteal muscle of the patient. Do not administer by any other route.
- h. After the injection is complete, use either thumb or finger of one hand (h1, h2) or a flat surface (h3) to activate the needle protection system. The needle protection system is fully activated when a 'click' is heard. Discard the syringe with needle appropriately.


**h1**



h2



h3



### 3 DOSAGE FORMS AND STRENGTHS

INVEGA® SUSTENNA® is available as a white to off-white aqueous extended-release injectable suspension for intramuscular injection in dose strengths of 39 mg, 78 mg, 117 mg, 156 mg, and 234 mg paliperidone palmitate.

### 4 CONTRAINDICATIONS

INVEGA® SUSTENNA® is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the INVEGA® SUSTENNA® formulation. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been observed in patients treated with risperidone and paliperidone. Paliperidone palmitate is converted to paliperidone, which is a metabolite of risperidone.

### 5 WARNINGS AND PRECAUTIONS

#### 5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course

of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> (paliperidone palmitate) is not approved for the treatment of patients with dementia-related psychosis [*see Boxed Warning*].

## **5.2 Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis**

In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. Oral paliperidone and INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> were not marketed at the time these studies were performed and are not approved for the treatment of patients with dementia-related psychosis [*see Boxed Warning and Warnings and Precautions (5.1)*].

## **5.3 Neuroleptic Malignant Syndrome**

A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs, including INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>.

Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases in which the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.

The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which

specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.

If a patient appears to require antipsychotic drug treatment after recovery from NMS, reintroduction of drug therapy should be closely monitored, since recurrences of NMS have been reported.

#### **5.4 QT Prolongation**

Paliperidone causes a modest increase in the corrected QT (QTc) interval. The use of paliperidone should be avoided in combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. Paliperidone should also be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.

Certain circumstances may increase the risk of the occurrence of Torsades de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval.

The effects of oral paliperidone on the QT interval were evaluated in a double-blind, active-controlled (moxifloxacin 400 mg single dose), multicenter QT study in adults with schizophrenia and schizoaffective disorder, and in three placebo- and active-controlled 6-week, fixed-dose efficacy trials in adults with schizophrenia.

In the QT study (n=141), the 8 mg dose of immediate-release oral paliperidone (n=50) showed a mean placebo-subtracted increase from baseline in QTcLD of 12.3 msec (90% CI: 8.9; 15.6) on day 8 at 1.5 hours post-dose. The mean steady-state peak plasma concentration for this 8 mg dose of paliperidone immediate release ( $C_{\max ss} = 113$  ng/mL) was more than 2-fold the exposure observed with the maximum recommended 234 mg dose of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> administered in the deltoid muscle (predicted median  $C_{\max ss} = 50$  ng/mL). In this same study, a 4 mg dose of the immediate-release oral formulation of paliperidone, for which  $C_{\max ss} = 35$  ng/mL, showed an increased placebo-subtracted QTcLD of 6.8 msec (90% CI: 3.6; 10.1) on day 2 at 1.5 hours post-dose.

In the three fixed-dose efficacy studies of oral paliperidone extended release in subjects with schizophrenia, electrocardiogram (ECG) measurements taken at various time points showed only one subject in the oral paliperidone 12 mg group had a change exceeding 60 msec at one time-point on Day 6 (increase of 62 msec).

In the four fixed-dose efficacy studies of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> in subjects with schizophrenia and in the long-term study in subjects with schizoaffective disorder, no subject experienced a change in QTcLD exceeding 60 msec and no subject had a QTcLD value of > 500 msec at any time point. In the maintenance study in subjects with schizophrenia, no subject had a QTcLD change > 60 msec, and one subject had a QTcLD value of 507 msec (Bazett's QT corrected interval [QTcB] value of 483 msec); this latter subject also had a heart rate of 45 beats per minute.

### **5.5 Tardive Dyskinesia**

A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to predict which patients will develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.

The risk of developing tardive dyskinesia and the likelihood that it will become irreversible appear to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase, but the syndrome can develop after relatively brief treatment periods at low doses, although this is uncommon.

There is no known treatment for established tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment itself may suppress (or partially suppress) the signs and symptoms of the syndrome and may thus mask the underlying process. The effect of symptomatic suppression on the long-term course of the syndrome is unknown.

Given these considerations, INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that is known to respond to antipsychotic drugs. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

If signs and symptoms of tardive dyskinesia appear in a patient treated with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>, drug discontinuation should be considered. However, some patients may require treatment with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> despite the presence of the syndrome.

### **5.6 Metabolic Changes**

Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia,

dyslipidemia, and body weight gain. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.

### Hyperglycemia and Diabetes Mellitus

Hyperglycemia and diabetes mellitus, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, have been reported in patients treated with all atypical antipsychotics. These cases were, for the most part, seen in post-marketing clinical use and epidemiologic studies, not in clinical trials, and there have been few reports of hyperglycemia or diabetes in trial subjects treated with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse reactions is not completely understood. However, epidemiological studies suggest an increased risk of hyperglycemia-related adverse reactions in patients treated with the atypical antipsychotics. Because INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> was not marketed at the time these studies were performed, it is not known if INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> is associated with this risk.

Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Pooled data from the four placebo-controlled (one 9-week and three 13-week), fixed-dose studies in subjects with schizophrenia are presented in Table 5.

**Table 5. Change in Fasting Glucose from Four Placebo-Controlled, 9- to 13-Week, Fixed-Dose Studies in Subjects with Schizophrenia**

|                                                                   | Placebo                                   | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup> |          |         |                        |                         |                         |
|-------------------------------------------------------------------|-------------------------------------------|-------------------------------------------|----------|---------|------------------------|-------------------------|-------------------------|
|                                                                   |                                           | 39 mg                                     | 78 mg    | 156 mg  | 234/39 mg <sup>a</sup> | 234/156 mg <sup>a</sup> | 234/234 mg <sup>a</sup> |
|                                                                   | n=367                                     | n=86                                      | n=244    | n=238   | n=110                  | n=126                   | n=115                   |
|                                                                   | Mean change from baseline (mg/dL)         |                                           |          |         |                        |                         |                         |
| <b>Serum Glucose Change from baseline</b>                         | -1.3                                      | 1.3                                       | 3.5      | 0.1     | 3.4                    | 1.8                     | -0.2                    |
|                                                                   | <b>Proportion of Patients with Shifts</b> |                                           |          |         |                        |                         |                         |
| <b>Serum Glucose Normal to High (&lt;100 mg/dL to ≥126 mg/dL)</b> | 4.6%                                      | 6.3%                                      | 6.4%     | 3.9%    | 2.5%                   | 7.0%                    | 6.6%                    |
|                                                                   | (11/241)                                  | (4/64)                                    | (11/173) | (6/154) | (2/79)                 | (6/86)                  | (5/76)                  |

<sup>a</sup> Initial deltoid injection of 234 mg followed by either 39 mg, 156 mg, or 234 mg every 4 weeks by deltoid or gluteal injection. Other dose groups (39 mg, 78 mg, and 156 mg) are from studies involving only gluteal injection. [See *Clinical Studies (14.1)*].

In a long-term open-label pharmacokinetic and safety study in subjects with schizophrenia in which the highest dose available (234 mg) was evaluated, INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> was associated with a mean change in glucose of -0.4 mg/dL at Week 29 (n=109) and +6.8 mg/dL at Week 53 (n=100).

During the initial 25-week open-label period of a long-term study in subjects with schizoaffective disorder, INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> was associated with mean change in glucose of +5.3 mg/dL (n=518). At the endpoint of the subsequent 15-month double-blind period of the study, INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> was associated with a mean change in glucose of +0.3 mg/dL (n=131) compared with a mean change of +4.0 mg/dL in the placebo group (n=120).

### Dyslipidemia

Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

Pooled data from the four placebo-controlled (one 9-week and three 13-week), fixed-dose studies in subjects with schizophrenia are presented in Table 6.

**Table 6. Change in Fasting Lipids from Four Placebo-Controlled, 9- to 13-Week, Fixed-Dose Studies in Subjects with Schizophrenia**

|                                                                   | Placebo           | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup> |                  |                   |                        |                         |                         |
|-------------------------------------------------------------------|-------------------|-------------------------------------------|------------------|-------------------|------------------------|-------------------------|-------------------------|
|                                                                   |                   | 39 mg                                     | 78 mg            | 156 mg            | 234/39 mg <sup>a</sup> | 234/156 mg <sup>a</sup> | 234/234 mg <sup>a</sup> |
| <b>Mean change from baseline (mg/dL)</b>                          |                   |                                           |                  |                   |                        |                         |                         |
| <b>Cholesterol Change from baseline</b>                           | n=366<br>-6.6     | n=89<br>-6.4                              | n=244<br>-5.8    | n=232<br>-7.1     | n=105<br>-0.9          | n=119<br>-4.2           | n=120<br>9.4            |
| <b>LDL Change from baseline</b>                                   | n=275<br>-6.0     | n=80<br>-4.8                              | n=164<br>-5.6    | n=141<br>-4.8     | n=104<br>0.9           | n=117<br>-2.4           | n=108<br>5.2            |
| <b>HDL Change from baseline</b>                                   | n=286<br>0.7      | n=89<br>2.1                               | n=165<br>0.6     | n=150<br>0.3      | n=105<br>1.5           | n=118<br>1.1            | n=115<br>0.0            |
| <b>Triglycerides Change from baseline</b>                         | n=366<br>-16.7    | n=89<br>7.6                               | n=244<br>-9.0    | n=232<br>-11.5    | n=105<br>-14.1         | n=119<br>-20.0          | n=120<br>11.9           |
| <b>Proportion of Patients with Shifts</b>                         |                   |                                           |                  |                   |                        |                         |                         |
| <b>Cholesterol Normal to High (&lt;200 mg/dL to ≥240 mg/dL)</b>   | 3.2%<br>(7/222)   | 2.0%<br>(1/51)                            | 2.0%<br>(3/147)  | 2.1%<br>(3/141)   | 0%<br>(0/69)           | 3.1%<br>(2/65)          | 7.1%<br>(6/84)          |
| <b>LDL Normal to High (&lt;100 mg/dL to ≥160 mg/dL)</b>           | 1.1%<br>(1/95)    | 0%<br>(0/29)                              | 0%<br>(0/67)     | 0%<br>(0/46)      | 0%<br>(0/41)           | 0%<br>(0/37)            | 0%<br>(0/44)            |
| <b>HDL Normal to Low (≥40 mg/dL to &lt;40 mg/dL)</b>              | 13.8%<br>(28/203) | 14.8%<br>(9/61)                           | 9.6%<br>(11/115) | 14.2%<br>(15/106) | 12.7%<br>(9/71)        | 10.5%<br>(8/76)         | 16.0%<br>(13/81)        |
| <b>Triglycerides Normal to High (&lt;150 mg/dL to ≥200 mg/dL)</b> | 3.6%<br>(8/221)   | 6.1%<br>(3/49)                            | 9.2%<br>(14/153) | 7.2%<br>(10/139)  | 1.3%<br>(1/79)         | 3.7%<br>(3/82)          | 10.7%<br>(9/84)         |

<sup>a</sup> Initial deltoid injection of 234 mg followed by either 39 mg, 156 mg, or 234 mg every 4 weeks by deltoid or gluteal injection. Other dose groups (39 mg, 78 mg, and 156 mg) are from studies involving only gluteal injection. [See Clinical Studies (14.1)].

In a long-term open-label pharmacokinetic and safety study in subjects with schizophrenia in which the highest dose available (234 mg) was evaluated, the mean changes from baseline in lipid values are presented in Table 7.

**Table 7. Change in Fasting Lipids from Long-term Open-label Pharmacokinetic and Safety Study in Subjects with Schizophrenia**

|                      | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup> 234 mg |              |
|----------------------|--------------------------------------------------|--------------|
|                      | Week 29                                          | Week 53      |
|                      | Mean change from baseline (mg/dL)                |              |
| <b>Cholesterol</b>   | <b>n=112</b>                                     | <b>n=100</b> |
| Change from baseline | -1.2                                             | 0.1          |
| <b>LDL</b>           | <b>n=107</b>                                     | <b>n=89</b>  |
| Change from baseline | -2.7                                             | -2.3         |
| <b>HDL</b>           | <b>n=112</b>                                     | <b>n=98</b>  |
| Change from baseline | -0.8                                             | -2.6         |
| <b>Triglycerides</b> | <b>n=112</b>                                     | <b>n=100</b> |
| Change from baseline | 16.2                                             | 37.4         |

The mean changes from baseline in lipid values during the initial 25-week open-label period and at the endpoint of the subsequent 15-month double-blind period in a long-term study in subjects with schizoaffective disorder are presented in Table 8.

**Table 8. Change in Fasting Lipids from an Open-Label and Double-Blind Periods of a Long-Term Study in Subjects with Schizoaffective Disorder**

|                                                   | Open-Label Period                            | Double-Blind Period  |                                           |
|---------------------------------------------------|----------------------------------------------|----------------------|-------------------------------------------|
|                                                   | INVEGA <sup>®</sup><br>SUSTENNA <sup>®</sup> | Placebo              | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup> |
|                                                   | Mean change from baseline (mg/dL)            |                      |                                           |
| <b>Cholesterol<br/>Change from<br/>baseline</b>   | <b>n=198</b><br>-3.9                         | <b>n=119</b><br>-4.2 | <b>n=132</b><br>2.3                       |
| <b>LDL<br/>Change from<br/>baseline</b>           | <b>n=198</b><br>-2.7                         | <b>n=117</b><br>-2.8 | <b>n=130</b><br>5.9                       |
| <b>HDL<br/>Change from<br/>baseline</b>           | <b>n=198</b><br>-2.7                         | <b>n=119</b><br>-0.9 | <b>n=131</b><br>-0.7                      |
| <b>Triglycerides<br/>Change from<br/>baseline</b> | <b>n=198</b><br>7.0                          | <b>n=119</b><br>2.5  | <b>n=132</b><br>-12.3                     |

### Weight Gain

Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

Data on mean changes in body weight and the proportion of subjects meeting a weight gain criterion of  $\geq 7\%$  of body weight from the four placebo-controlled (one 9-week and three 13-week), fixed-dose studies in subjects with schizophrenia are presented in Table 9.

**Table 9. Mean Change in Body Weight (kg) and the Proportion of Subjects with  $\geq 7\%$  Gain in Body Weight from Four Placebo-Controlled, 9- to 13-Week, Fixed-Dose Studies in Subjects with Schizophrenia**

|                                                                 | Placebo<br>n=451 | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup> |                |                 |                                 |                                  |                                  |
|-----------------------------------------------------------------|------------------|-------------------------------------------|----------------|-----------------|---------------------------------|----------------------------------|----------------------------------|
|                                                                 |                  | 39 mg<br>n=116                            | 78 mg<br>n=280 | 156 mg<br>n=267 | 234/39 mg <sup>a</sup><br>n=137 | 234/156 mg <sup>a</sup><br>n=144 | 234/234 mg <sup>a</sup><br>n=145 |
| <b>Weight (kg) Change from baseline</b>                         | -0.4             | 0.4                                       | 0.8            | 1.4             | 0.4                             | 0.7                              | 1.4                              |
| <b>Weight Gain <math>\geq 7\%</math> increase from baseline</b> | 3.3%             | 6.0%                                      | 8.9%           | 9.0%            | 5.8%                            | 8.3%                             | 13.1%                            |

<sup>a</sup> Initial deltoid injection of 234 mg followed by either 39 mg, 156 mg, or 234 mg every 4 weeks by deltoid or gluteal injection. Other dose groups (39 mg, 78 mg, and 156 mg) are from studies involving only gluteal injection. [See *Clinical Studies (14.1)*].

In a long-term open-label pharmacokinetic and safety study in which the highest dose available (234 mg) was evaluated, INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> was associated with a mean change in weight of +2.4 kg at Week 29 (n=134) and +4.3 kg at Week 53 (n=113).

During the initial 25-week open-label period of a long-term study in subjects with schizoaffective disorder, INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> was associated with a mean change in weight of +2.2 kg and 18.4% of subjects had an increase in body weight of  $\geq 7\%$  (n=653). At the endpoint of the subsequent 15-month double-blind period of the study, INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> was associated with a mean change in weight of -0.2 kg and 13.0% of subjects had an increase in body weight of  $\geq 7\%$  (n=161); the placebo group had a mean change in weight of -0.8 kg and 6.0% of subjects had an increase in body weight of  $\geq 7\%$  (n=168).

## 5.7 Orthostatic Hypotension and Syncope

Paliperidone can induce orthostatic hypotension and syncope in some patients because of its alpha-blocking activity. Syncope was reported in  $< 1\%$  (4/1293) of subjects treated with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> in the recommended dose range of 39 mg to 234 mg in the four fixed-dose, double-blind, placebo-controlled trials compared with 0% (0/510) of subjects treated with placebo. In the four fixed-dose efficacy studies in subjects with schizophrenia, orthostatic hypotension was reported as an adverse event by  $< 1\%$  (2/1293) of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>-treated subjects compared to 0% (0/510) with placebo. Incidences of orthostatic hypotension and syncope in the long-term studies in subjects with schizophrenia and schizoaffective disorder were similar to those observed in the short-term studies.

INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> should be used with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). Monitoring of orthostatic vital signs should be considered in patients who are vulnerable to hypotension.

### **5.8 Leukopenia, Neutropenia, and Agranulocytosis**

In clinical trial and/or postmarketing experience, events of leukopenia/neutropenia have been reported temporally related to antipsychotic agents, including INVEGA<sup>®</sup>, an oral form of paliperidone. Agranulocytosis has also been reported.

Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug-induced leukopenia/neutropenia. Patients with a history of a clinically significant low WBC or a drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.

Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count  $<1000/\text{mm}^3$ ) should discontinue INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> and have their WBC followed until recovery.

### **5.9 Hyperprolactinemia**

Like other drugs that antagonize dopamine D<sub>2</sub> receptors, paliperidone elevates prolactin levels and the elevation persists during chronic administration. Paliperidone has a prolactin-elevating effect similar to that seen with risperidone, a drug that is associated with higher levels of prolactin than other antipsychotic drugs.

Hyperprolactinemia, regardless of etiology, may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotrophin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.

Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent *in vitro*, a factor of potential importance if the prescription of these drugs is considered in a patient with previously detected breast cancer. An increase in the incidence of pituitary gland, mammary gland, and pancreatic islet cell neoplasia (mammary adenocarcinomas,

pituitary and pancreatic adenomas) was observed in the risperidone carcinogenicity studies conducted in mice and rats [see *Nonclinical Toxicology (13.1)*]. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.

### **5.10 Potential for Cognitive and Motor Impairment**

Somnolence, sedation, and dizziness were reported as adverse reactions in subjects treated with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> [see *Adverse Reactions (6.1)*]. Antipsychotics, including INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>, have the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about performing activities requiring mental alertness, such as operating hazardous machinery or operating a motor vehicle, until they are reasonably certain that paliperidone therapy does not adversely affect them.

### **5.11 Seizures**

In the four fixed-dose double-blind placebo-controlled studies in subjects with schizophrenia, <1% (1/1293) of subjects treated with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> in the recommended dose range of 39 mg to 234 mg experienced an adverse event of convulsion compared with <1% (1/510) of placebo-treated subjects who experienced an adverse event of grand mal convulsion.

Like other antipsychotic drugs, INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold. Conditions that lower the seizure threshold may be more prevalent in patients 65 years or older.

### **5.12 Dysphagia**

Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in patients with advanced Alzheimer's dementia. INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

### **5.13 Priapism**

Drugs with alpha-adrenergic blocking effects have been reported to induce priapism. Although no cases of priapism have been reported in clinical trials with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>, priapism has been reported with oral paliperidone during postmarketing surveillance. Severe priapism may require surgical intervention.

### **5.14 Disruption of Body Temperature Regulation**

Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> to patients who will be experiencing conditions which may contribute to an elevation in core body

temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration.

## 6 ADVERSE REACTIONS

The following are discussed in more detail in other sections of the labeling:

- Increased mortality in elderly patients with dementia-related psychosis [*see Boxed Warning and Warnings and Precautions (5.1)*]
- Cerebrovascular adverse reactions, including stroke, in elderly patients with dementia-related psychosis [*see Warnings and Precautions (5.2)*]
- Neuroleptic malignant syndrome [*see Warnings and Precautions (5.3)*]
- QT prolongation [*see Warnings and Precautions (5.4)*]
- Tardive dyskinesia [*see Warnings and Precautions (5.5)*]
- Metabolic changes [*see Warnings and Precautions (5.6)*]
- Orthostatic hypotension and syncope [*see Warnings and Precautions (5.7)*]
- Leukopenia, neutropenia, and agranulocytosis [*see Warnings and Precautions (5.8)*]
- Hyperprolactinemia [*See Warnings and Precautions (5.9)*]
- Potential for cognitive and motor impairment [*see Warnings and Precautions (5.10)*]
- Seizures [*see Warnings and Precautions (5.11)*]
- Dysphagia [*see Warnings and Precautions (5.12)*]
- Priapism [*see Warnings and Precautions (5.13)*]
- Disruption of body temperature regulation [*see Warnings and Precautions (5.14)*]

The most common (at least 5% in any INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> group) and likely drug-related (adverse events for which the drug rate is at least twice the placebo rate) adverse reactions from the double-blind, placebo-controlled trials in subjects with schizophrenia were injection site reactions, somnolence/sedation, dizziness, akathisia, and extrapyramidal disorder. No occurrences of adverse events reached this threshold in the long-term double-blind, placebo-controlled study in subjects with schizoaffective disorder.

The data described in this section are derived from a clinical trial database consisting of a total of 3817 subjects (approximately 1705 patient-years exposure) with schizophrenia who received at least one dose of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> in the recommended dose range of 39 mg to 234 mg and a total of 510 subjects with schizophrenia who received placebo. Among the 3817 INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>-treated subjects, 1293 received INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> in four fixed-dose, double-blind, placebo-controlled trials (one 9-week and three 13-week studies), 849 received INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> in the maintenance trial (median exposure 229 days during the initial 33-week open-label phase of this study, of whom 205 continued to receive INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> during the double-blind placebo-controlled phase of this study [median exposure 171 days]), and 1675 received INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> in five non-placebo controlled trials (three noninferiority active-comparator trials, one long-term open-label pharmacokinetic and safety study, and an injection site [deltoid-gluteal] cross-over trial). One of the 13-week studies included a 234 mg INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> initiation dose followed by treatment with either 39 mg, 156 mg, or 234 mg every 4 weeks.

The safety of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> was also evaluated in a long-term study in adult subjects with schizoaffective disorder. A total of 667 subjects received INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> during the initial 25-week open-label period of this study (median exposure 147 days); 164 subjects continued to receive INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> during the 15-month double-blind placebo-controlled period of this study (median exposure 446 days). Adverse reactions that occurred more frequently in the INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> than the placebo group (a 2% difference or more between groups) were weight increased, nasopharyngitis, headache, hyperprolactinemia, and pyrexia.

## **6.1 Clinical Trials Experience**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

### **Commonly Reported Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials**

Table 10 lists the adverse reactions reported in 2% or more of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>-treated subjects and at a greater proportion than in the placebo group with schizophrenia in the four fixed-dose, double-blind, placebo-controlled trials.

**Table 10. Incidence of Adverse Reactions in ≥ 2% of INVEGA® SUSTENNA®-Treated Subjects (and greater than Placebo) with Schizophrenia in Four Fixed-Dose, Double-Blind, Placebo-Controlled Trials**

| System Organ Class<br>Adverse Event                         | Placebo <sup>a</sup><br>(N=510) | INVEGA® SUSTENNA® |                  |                   |                                   |                                    |                                    |
|-------------------------------------------------------------|---------------------------------|-------------------|------------------|-------------------|-----------------------------------|------------------------------------|------------------------------------|
|                                                             |                                 | 39 mg<br>(N=130)  | 78 mg<br>(N=302) | 156 mg<br>(N=312) | 234/39 mg <sup>b</sup><br>(N=160) | 234/156 mg <sup>b</sup><br>(N=165) | 234/234 mg <sup>b</sup><br>(N=163) |
| Total percentage of subjects with adverse event             | 70                              | 75                | 68               | 69                | 63                                | 60                                 | 63                                 |
| <b>Gastrointestinal disorders</b>                           |                                 |                   |                  |                   |                                   |                                    |                                    |
| Abdominal discomfort/abdominal pain upper                   | 2                               | 2                 | 4                | 4                 | 1                                 | 2                                  | 4                                  |
| Diarrhea                                                    | 2                               | 0                 | 3                | 2                 | 1                                 | 2                                  | 2                                  |
| Dry mouth                                                   | 1                               | 3                 | 1                | 0                 | 1                                 | 1                                  | 1                                  |
| Nausea                                                      | 3                               | 4                 | 4                | 3                 | 2                                 | 2                                  | 2                                  |
| Toothache                                                   | 1                               | 1                 | 1                | 3                 | 1                                 | 2                                  | 3                                  |
| Vomiting                                                    | 4                               | 5                 | 4                | 2                 | 3                                 | 2                                  | 2                                  |
| <b>General disorders and administration site conditions</b> |                                 |                   |                  |                   |                                   |                                    |                                    |
| Asthenia                                                    | 0                               | 2                 | 1                | <1                | 0                                 | 1                                  | 1                                  |
| Fatigue                                                     | 1                               | 1                 | 2                | 2                 | 1                                 | 2                                  | 1                                  |
| Injection site reactions                                    | 2                               | 0                 | 4                | 6                 | 9                                 | 7                                  | 10                                 |
| <b>Infections and infestations</b>                          |                                 |                   |                  |                   |                                   |                                    |                                    |
| Nasopharyngitis                                             | 2                               | 0                 | 2                | 2                 | 4                                 | 2                                  | 2                                  |
| Upper respiratory tract infection                           | 2                               | 2                 | 2                | 2                 | 1                                 | 2                                  | 4                                  |
| Urinary tract infection                                     | 1                               | 0                 | 1                | <1                | 1                                 | 1                                  | 2                                  |
| <b>Investigations</b>                                       |                                 |                   |                  |                   |                                   |                                    |                                    |
| Weight increased                                            | 1                               | 4                 | 4                | 1                 | 1                                 | 1                                  | 2                                  |
| <b>Musculoskeletal and connective tissue disorders</b>      |                                 |                   |                  |                   |                                   |                                    |                                    |
| Back pain                                                   | 2                               | 2                 | 1                | 3                 | 1                                 | 1                                  | 1                                  |
| Musculoskeletal stiffness                                   | 1                               | 1                 | <1               | <1                | 1                                 | 1                                  | 2                                  |
| Myalgia                                                     | 1                               | 2                 | 1                | <1                | 1                                 | 0                                  | 2                                  |
| Pain in extremity                                           | 1                               | 0                 | 2                | 2                 | 2                                 | 3                                  | 0                                  |
| <b>Nervous system disorders</b>                             |                                 |                   |                  |                   |                                   |                                    |                                    |
| Akathisia                                                   | 3                               | 2                 | 2                | 3                 | 1                                 | 5                                  | 6                                  |
| Dizziness                                                   | 1                               | 6                 | 2                | 4                 | 1                                 | 4                                  | 2                                  |
| Extrapyramidal disorder                                     | 1                               | 5                 | 2                | 3                 | 1                                 | 0                                  | 0                                  |
| Headache                                                    | 12                              | 11                | 11               | 15                | 11                                | 7                                  | 6                                  |
| Somnolence/sedation                                         | 3                               | 5                 | 7                | 4                 | 1                                 | 5                                  | 5                                  |
| <b>Psychiatric disorders</b>                                |                                 |                   |                  |                   |                                   |                                    |                                    |
| Agitation                                                   | 7                               | 10                | 5                | 9                 | 8                                 | 5                                  | 4                                  |
| Anxiety                                                     | 7                               | 8                 | 5                | 3                 | 5                                 | 6                                  | 6                                  |
| Nightmare                                                   | <1                              | 2                 | 0                | 0                 | 0                                 | 0                                  | 0                                  |
| <b>Respiratory, thoracic and mediastinal disorders</b>      |                                 |                   |                  |                   |                                   |                                    |                                    |
| Cough                                                       | 1                               | 2                 | 3                | 1                 | 0                                 | 1                                  | 1                                  |
| <b>Vascular disorders</b>                                   |                                 |                   |                  |                   |                                   |                                    |                                    |
| Hypertension                                                | 1                               | 2                 | 1                | 1                 | 1                                 | 1                                  | 0                                  |

Percentages are rounded to whole numbers. Table includes adverse events that were reported in 2% or more of subjects in any of the INVEGA® SUSTENNA® dose groups and which occurred at greater incidence than in the placebo group.

<sup>a</sup> Placebo group is pooled from all studies and included either deltoid or gluteal injection depending on study design.

<sup>b</sup> Initial deltoid injection of 234 mg followed by either 39 mg, 156 mg, or 234 mg every 4 weeks by deltoid or gluteal injection. Other dose groups (39 mg, 78 mg, and 156 mg) are from studies involving only gluteal injection. [See Clinical Studies (14.1)]

Adverse events for which the INVEGA® SUSTENNA® incidence was equal to or less than placebo are not listed in the table, but included the following: dyspepsia, psychotic disorder, schizophrenia, and tremor. The following terms were combined: somnolence/sedation, breast tenderness/breast pain, abdominal discomfort/abdominal pain upper/stomach discomfort, and tachycardia/sinus tachycardia/heart rate increased. All injection site reaction-related adverse events were collapsed and are grouped under "Injection site reactions".

## Other Adverse Reactions Observed During the Clinical Trial Evaluation of INVEGA® SUSTENNA®

The following list does not include reactions: 1) already listed in previous tables or elsewhere in labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, or 4) which were not considered to have significant clinical implications.

**Cardiac disorders:** atrioventricular block first degree, bradycardia, bundle branch block, palpitations, postural orthostatic tachycardia syndrome, tachycardia

**Ear and labyrinth disorders:** vertigo

**Eye disorders:** eye movement disorder, eye rolling, oculogyric crisis, vision blurred

**Gastrointestinal disorders:** constipation, dyspepsia, flatulence, salivary hypersecretion

**Immune system disorders:** hypersensitivity

**Investigations:** alanine aminotransferase increased, aspartate aminotransferase increased, electrocardiogram abnormal

**Metabolism and nutrition disorders:** decreased appetite, hyperinsulinemia, increased appetite

**Musculoskeletal and connective tissue disorders:** arthralgia, joint stiffness, muscle rigidity, muscle spasms, muscle tightness, muscle twitching, nuchal rigidity

**Nervous system disorders:** bradykinesia, cerebrovascular accident, convulsion, dizziness postural, drooling, dysarthria, dyskinesia, dystonia, hypertonia, lethargy, oromandibular dystonia, parkinsonism, psychomotor hyperactivity, syncope

**Psychiatric disorders:** insomnia, restlessness

**Reproductive system and breast disorders:** amenorrhea, breast discharge, erectile dysfunction, galactorrhea, gynecomastia, menstrual disorder, menstruation delayed, menstruation irregular, sexual dysfunction

**Respiratory, thoracic and mediastinal disorders:** nasal congestion

**Skin and subcutaneous tissue disorders:** drug eruption, pruritus, pruritus generalized, rash, urticaria

### Discontinuations Due to Adverse Events

The percentage of subjects who discontinued due to adverse events in the four fixed-dose, double-blind, placebo-controlled schizophrenia trials were similar for INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> - and placebo-treated subjects.

The percentage of subjects who discontinued due to adverse events in the open-label period of the long-term study in subjects with schizoaffective disorder was 7.5%. During the double-blind, placebo-controlled period of that study, the percentages of subjects who discontinued due to adverse events were 5.5% and 1.8% in INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> - and placebo-treated subjects, respectively.

### Dose-Related Adverse Reactions

Based on the pooled data from the four fixed-dose, double-blind, placebo-controlled trials in subjects with schizophrenia, among the adverse reactions that occurred at  $\geq 2\%$  incidence in the subjects treated with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>, only akathisia increased with dose. Hyperprolactinemia also exhibited a dose relationship, but did not occur at  $\geq 2\%$  incidence in INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>-treated subjects from the four fixed-dose studies.

### Demographic Differences

An examination of population subgroups in the double-blind placebo-controlled trials did not reveal any evidence of differences in safety on the basis of age, gender, or race alone; however, there were few subjects  $\geq 65$  years of age.

### Extrapyramidal Symptoms (EPS)

Pooled data from the two double-blind, placebo-controlled, 13-week, fixed-dose trials in adult subjects with schizophrenia provided information regarding EPS. Several methods were used to measure EPS: (1) the Simpson-Angus global score (mean change from baseline or score at the end of trial) which broadly evaluates Parkinsonism, (2) the Barnes Akathisia Rating Scale global clinical rating score (mean change from baseline or score at the end of trial) which evaluates akathisia, (3) use of anticholinergic medications to treat EPS, (4) the Abnormal Involuntary Movement Scale scores (mean change from baseline or scores at the end of trial) (Table 11), and (5) incidence of spontaneous reports of EPS (Table 12).

**Table 11. Extrapyrarnidal Symptoms (EPS) Assessed by Incidence of Rating Scales and Use of Anticholinergic Medication – Schizophrenia Studies in Adults**

| Scale                                           | Percentage of Subjects                    |                  |                  |                   |
|-------------------------------------------------|-------------------------------------------|------------------|------------------|-------------------|
|                                                 | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup> |                  |                  |                   |
|                                                 | Placebo<br>(N=262)                        | 39 mg<br>(N=130) | 78 mg<br>(N=223) | 156 mg<br>(N=228) |
| Parkinsonism <sup>a</sup>                       | 9                                         | 12               | 10               | 6                 |
| Akathisia <sup>b</sup>                          | 5                                         | 5                | 6                | 5                 |
| Dyskinesia <sup>c</sup>                         | 3                                         | 4                | 6                | 4                 |
| Use of Anticholinergic Medications <sup>d</sup> | 12                                        | 10               | 12               | 11                |

<sup>a</sup> For Parkinsonism, percent of subjects with Simpson-Angus Total score > 0.3 at endpoint (Total score defined as total sum of items score divided by the number of items)

<sup>b</sup> For Akathisia, percent of subjects with Barnes Akathisia Rating Scale global score ≥ 2 at endpoint

<sup>c</sup> For Dyskinesia, percent of subjects with a score ≥ 3 on any of the first 7 items or a score ≥ 2 on two or more of any of the first 7 items of the Abnormal Involuntary Movement Scale at endpoint

<sup>d</sup> Percent of subjects who received anticholinergic medications to treat EPS

**Table 12. Extrapyrarnidal Symptoms (EPS)-Related Events by MedDRA Preferred Term – Schizophrenia Studies in Adults**

| EPS Group                                                      | Percentage of Subjects                    |                  |                  |                   |
|----------------------------------------------------------------|-------------------------------------------|------------------|------------------|-------------------|
|                                                                | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup> |                  |                  |                   |
|                                                                | Placebo<br>(N=262)                        | 39 mg<br>(N=130) | 78 mg<br>(N=223) | 156 mg<br>(N=228) |
| Overall percentage of subjects with EPS-related adverse events | 10                                        | 12               | 11               | 11                |
| Parkinsonism                                                   | 5                                         | 6                | 6                | 4                 |
| Hyperkinesia                                                   | 2                                         | 2                | 2                | 4                 |
| Tremor                                                         | 3                                         | 2                | 2                | 3                 |
| Dyskinesia                                                     | 1                                         | 2                | 3                | 1                 |
| Dystonia                                                       | 0                                         | 1                | 1                | 2                 |

Parkinsonism group includes: Extrapyrarnidal disorder, hypertonia, musculoskeletal stiffness, parkinsonism, drooling, masked facies, muscle tightness, hypokinesia

Hyperkinesia group includes: Akathisia, restless legs syndrome, restlessness

Dyskinesia group includes: Dyskinesia, choreoathetosis, muscle twitching, myoclonus, tardive dyskinesia

Dystonia group includes: Dystonia, muscle spasms

The results across all phases of the maintenance trial in subjects with schizophrenia exhibited comparable findings. In the 9-week, fixed-dose, double-blind, placebo-controlled trial, the proportions of Parkinsonism and akathisia assessed by incidence of rating scales were higher in the INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> 156 mg group (18% and 11%, respectively) than in the INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> 78 mg group (9% and 5%, respectively) and placebo group (7% and 4%, respectively).

In the 13-week study in subjects with schizophrenia involving 234 mg initiation dosing, the incidence of any EPS was similar to that of the placebo group (8%), but exhibited a dose-related pattern with 6%, 10%, and 11% in the INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> 234/39 mg, 234/156 mg, and 234/234 mg groups, respectively. Hyperkinesia was the most frequent category of EPS-related adverse events in this study, and was reported at a similar rate between the placebo (4.9%) and

INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> 234/156 mg (4.8%) and 234/234 mg (5.5%) groups, but at a lower rate in the 234/39 mg group (1.3%).

In the long-term study in subjects with schizoaffective disorder, the EPS during the 25-week open-label INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> treatment were hyperkinesia (12.3%), parkinsonism (8.7%), tremor (3.4%), dyskinesia (2.5%), and dystonia (2.1%). During the 15-month double-blind treatment, the incidence of any EPS was similar to that of the placebo group (8.5% and 7.1% respectively). The most commonly reported treatment-emergent EPS-related adverse events (>2%) in any treatment group in the double-blind phase of the study (INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> versus placebo) were hyperkinesia (3.7% vs. 2.9%), parkinsonism (3.0% vs. 1.8%), and tremor (1.2% vs. 2.4%).

### Dystonia

Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

### Laboratory Test Abnormalities

In the pooled data from the two double-blind, placebo-controlled, 13-week, fixed-dose trials in subjects with schizophrenia, a between-group comparison revealed no medically important differences between INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> and placebo in the proportions of subjects experiencing potentially clinically significant changes in routine serum chemistry, hematology, or urinalysis parameters. Similarly, there were no differences between INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> and placebo in the incidence of discontinuations due to changes in hematology, urinalysis, or serum chemistry, including mean changes from baseline in fasting glucose, insulin, c-peptide, triglycerides, HDL, LDL, and total cholesterol measurements. However, INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> was associated with increases in serum prolactin [*see Warnings and Precautions (5.9)*]. The results from the 13-week study involving 234 mg initiation dosing, the 9-week, fixed-dose, double-blind, placebo-controlled trial, and the double-blind phase of the maintenance trial in subjects with schizophrenia exhibited comparable findings.

### Pain Assessment and Local Injection Site Reactions

In the pooled data from the two 13-week, fixed-dose, double-blind, placebo-controlled trials in subjects with schizophrenia, the mean intensity of injection pain reported by subjects using a visual analog scale (0 = no pain to 100 = unbearably painful) decreased in all treatment groups from the

first to the last injection (placebo: 10.9 to 9.8; 39 mg: 10.3 to 7.7; 78 mg: 10.0 to 9.2; 156 mg: 11.1 to 8.8). The results from both the 9-week, fixed-dose, double-blind, placebo-controlled trial and the double-blind phase of the maintenance trial exhibited comparable findings.

In the 13-week study involving 234 mg initiation dosing in subjects with schizophrenia, occurrences of induration, redness, or swelling, as assessed by blinded study personnel, were infrequent, generally mild, decreased over time, and similar in incidence between the INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> and placebo groups. Investigator ratings of injection pain were similar for the placebo and INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> groups. Investigator evaluations of the injection site after the first injection for redness, swelling, induration, and pain were rated as absent for 69-100% of subjects in both the INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> and placebo groups. At Day 92, investigators rated absence of redness, swelling, induration, and pain in 95-100% of subjects in both the INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> and placebo groups.

#### **Adverse Reactions Reported in Clinical Trials with Oral Paliperidone**

The following is a list of additional adverse reactions that have been reported in clinical trials with oral paliperidone:

**Cardiac disorders:** bundle branch block left, sinus arrhythmia

**Gastrointestinal disorders:** abdominal pain, small intestinal obstruction

**General disorders and administration site conditions:** edema, edema peripheral

**Immune system disorders:** anaphylactic reaction

**Infections and infestations:** rhinitis

**Musculoskeletal and connective tissue disorders:** musculoskeletal pain, torticollis, trismus

**Nervous system disorders:** cogwheel rigidity, grand mal convulsion, parkinsonian gait, transient ischemic attack

**Psychiatric disorders:** sleep disorder

**Reproductive system and breast disorders:** breast engorgement, breast tenderness/breast pain, retrograde ejaculation

**Respiratory, thoracic and mediastinal disorders:** pharyngolaryngeal pain, pneumonia aspiration

**Skin and subcutaneous tissue disorders:** rash papular

**Vascular disorders:** hypotension, ischemia

## **6.2 Postmarketing Experience**

The following adverse reactions have been identified during postapproval use of paliperidone; because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Reactions already listed in other parts of *ADVERSE REACTIONS (6)*, or those considered in *WARNINGS AND PRECAUTIONS (5)* are not listed here.

**Blood disorders:** thrombotic thrombocytopenic purpura

**Gastrointestinal disorders:** ileus

**Genitourinary disorders:** urinary incontinence, urinary retention

**Immune system disorders:** angioedema, swollen tongue

Cases of anaphylactic reaction after injection with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> have been reported during postmarketing experience in patients who have previously tolerated oral risperidone or oral paliperidone.

## **6.3 Adverse Reactions Reported With Risperidone**

Paliperidone is the major active metabolite of risperidone. Adverse reactions reported with oral risperidone and risperidone long-acting injection can be found in the *ADVERSE REACTIONS* sections of the package inserts for those products.

## **7 DRUG INTERACTIONS**

Because paliperidone palmitate is hydrolyzed to paliperidone [*see Clinical Pharmacology (12.3)*], results from studies with oral paliperidone should be taken into consideration when assessing drug-drug interaction potential.

### **7.1 Potential for INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> to Affect Other Drugs**

Paliperidone may antagonize the effect of levodopa and other dopamine agonists.

Because of its potential for inducing orthostatic hypotension, an additive effect may occur when INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> is administered with other therapeutic agents that have this potential [*see Warnings and Precautions (5.7)*].

No dose adjustment is necessary for lithium when it is coadministered with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>. Pharmacokinetic interaction between INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> and lithium is unlikely.

No dose adjustment is necessary for valproate when INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> is added to the

therapy. Steady-state pharmacokinetics of valproate was not affected when patients were coadministered oral paliperidone extended-release tablets [see *Clinical Pharmacology (12.3)*].

Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes [see *Clinical Pharmacology (12.3)*].

## **7.2 Potential for Other Drugs to Affect INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>**

On initiation of strong inducers of both CYP3A4 and P-gp (e.g., carbamazepine, rifampin, or St John's wort), it may be necessary to increase the dose of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>. Conversely, on discontinuation of the strong inducer, it may be necessary to decrease the dose of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> [see *Clinical Pharmacology (12.3)*].

No dose adjustment is necessary for INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> when valproate is added to treatment [see *Clinical Pharmacology (12.3)*].

No dose adjustment is necessary for INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> when it is coadministered with lithium. Pharmacokinetic interaction between INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> and lithium is unlikely.

*In vitro* studies indicate that CYP2D6 and CYP3A4 may be involved in paliperidone metabolism; however, there is no evidence *in vivo* that inhibitors of these enzymes significantly affect the metabolism of paliperidone. Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19; an interaction with inhibitors or inducers of these isozymes is unlikely.

## **8 USE IN SPECIFIC POPULATIONS**

### **8.1 Pregnancy**

#### **Pregnancy Category C**

##### **Risk Summary**

Adequate and well controlled studies with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> have not been conducted in pregnant women. Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

##### **Clinical Considerations**

##### ***Fetal/Neonatal Adverse Reactions***

Monitor neonates exhibiting extrapyramidal or withdrawal symptoms. Some neonates recover within hours or days without specific treatment; others may require prolonged hospitalization.

## Data

### *Human Data*

There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder in neonates following *in utero* exposure to antipsychotics in the third trimester. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.

### *Animal Data*

There were no treatment-related effects on the offspring when pregnant rats were injected intramuscularly with paliperidone palmitate during the period of organogenesis at doses up to 250 mg/kg, which is 10 times the maximum recommended human 234 mg dose of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> on a mg/m<sup>2</sup> body surface area basis.

In studies in pregnant rats and rabbits in which paliperidone was given orally during the period of organogenesis, there were no increases in fetal abnormalities up to the highest doses tested (10 mg/kg/day in rats and 5 mg/kg/day in rabbits, which are each 8 times the maximum recommended human dose of 12 mg/day of orally administered paliperidone [INVEGA<sup>®</sup>] on a mg/m<sup>2</sup> body surface area basis).

In rat reproduction studies with risperidone, which is extensively converted to paliperidone in rats and humans, increases in pup deaths were seen at oral doses which are less than the maximum recommended human dose of risperidone on a mg/m<sup>2</sup> body surface area basis (see RISPERDAL<sup>®</sup> package insert).

## **8.2 Labor and Delivery**

The effect of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> on labor and delivery in humans is unknown.

## **8.3 Nursing Mothers**

In animal studies with paliperidone and in human studies with risperidone, paliperidone was excreted in the milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

## **8.4 Pediatric Use**

Safety and effectiveness of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> in patients < 18 years of age have not been established.

In a study in which juvenile rats were treated with oral paliperidone from days 24 to 73 of age, a reversible impairment of performance in a test of learning and memory was seen, in females

only, with a no-effect dose of 0.63 mg/kg/day, which produced plasma levels (AUC) of paliperidone similar to those in adolescents. No other consistent effects on neurobehavioral or reproductive development were seen up to the highest dose tested (2.5 mg/kg/day), which produced plasma levels of paliperidone 2-3 times those in adolescents.

Juvenile dogs were treated for 40 weeks with oral risperidone, which is extensively metabolized to paliperidone in animals and humans, at doses of 0.31, 1.25, or 5 mg/kg/day. Decreased bone length and density were seen with a no-effect dose of 0.31 mg/kg/day, which produced plasma levels (AUC) of risperidone plus paliperidone which were similar to those in children and adolescents receiving the maximum recommended human dose of risperidone. In addition, a delay in sexual maturation was seen at all doses in both males and females. The above effects showed little or no reversibility in females after a 12-week drug-free recovery period.

The long-term effects of paliperidone on growth and sexual maturation have not been fully evaluated in children and adolescents.

### **8.5 Geriatric Use**

Clinical studies of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

This drug is known to be substantially excreted by the kidney and clearance is decreased in patients with renal impairment [*see Clinical Pharmacology (12.3)*], who should be given reduced doses. Because elderly patients are more likely to have decreased renal function, adjust dose based on renal function [*see Dosage and Administration (2.5)*].

### **8.6 Renal Impairment**

Use of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> is not recommended in patients with moderate or severe renal impairment (creatinine clearance < 50 mL/min). Dose reduction is recommended for patients with mild renal impairment (creatinine clearance ≥ 50 mL/min to < 80 mL/min) [*see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)*].

### **8.7 Hepatic Impairment**

INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> has not been studied in patients with hepatic impairment. Based on a study with oral paliperidone, no dose adjustment is required in patients with mild or moderate hepatic impairment. Paliperidone has not been studied in patients with severe hepatic impairment.

## **8.8 Patients with Parkinson's Disease or Lewy Body Dementia**

Patients with Parkinson's Disease or Dementia with Lewy Bodies can experience increased sensitivity to INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>. Manifestations can include confusion, obtundation, postural instability with frequent falls, extrapyramidal symptoms, and clinical features consistent with neuroleptic malignant syndrome.

## **9 DRUG ABUSE AND DEPENDENCE**

### **9.1 Controlled Substance**

INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> (paliperidone) is not a controlled substance.

### **9.2 Abuse**

Paliperidone has not been systematically studied in animals or humans for its potential for abuse.

### **9.3 Dependence**

Paliperidone has not been systematically studied in animals or humans for its potential for tolerance or physical dependence.

## **10 OVERDOSAGE**

### **10.1 Human Experience**

No cases of overdose were reported in premarketing studies with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>. Because INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> is to be administered by health care professionals, the potential for overdose by patients is low.

While experience with paliperidone overdose is limited, among the few cases of overdose reported in premarketing trials with oral paliperidone, the highest estimated ingestion was 405 mg. Observed signs and symptoms included extrapyramidal symptoms and gait unsteadiness. Other potential signs and symptoms include those resulting from an exaggeration of paliperidone's known pharmacological effects, i.e., drowsiness and sedation, tachycardia and hypotension, and QT prolongation. Torsades de pointes and ventricular fibrillation have been reported in a patient in the setting of overdose with oral paliperidone.

Paliperidone is the major active metabolite of risperidone. Overdose experience reported with risperidone can be found in the *OVERDOSAGE* section of the risperidone package insert.

### **10.2 Management of Overdosage**


Contact a Certified Poison Control Center for the most up to date information on the management of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> overdose (1-800-222-1222 or [www.poison.org](http://www.poison.org)). Provide supportive care, including close medical supervision and monitoring. Treatment should consist of general measures employed in the management of overdose with any drug. Consider the possibility of multiple drug overdose. Ensure an adequate airway, oxygenation, and

ventilation. Monitor cardiac rhythm and vital signs. Use supportive and symptomatic measures. There is no specific antidote to paliperidone.

Consider the prolonged-release characteristics of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> and the long apparent half-life of paliperidone when assessing treatment needs and recovery.

## 11 DESCRIPTION

INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> is an atypical antipsychotic. INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> contains paliperidone palmitate. The active ingredient, paliperidone palmitate, is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives. INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> contains a racemic mixture of (+)- and (-)- paliperidone palmitate. The chemical name is (9*RS*)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-4-oxo-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-9-yl hexadecanoate. Its molecular formula is C<sub>39</sub>H<sub>57</sub>FN<sub>4</sub>O<sub>4</sub> and its molecular weight is 664.89. The structural formula is:



Paliperidone palmitate is very slightly soluble in ethanol and methanol, practically insoluble in polyethylene glycol 400 and propylene glycol, and slightly soluble in ethyl acetate.

INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> is available as a white to off-white sterile aqueous extended-release suspension for intramuscular injection in the following dose strengths of paliperidone palmitate (and deliverable volumes of the prefilled syringes): 39 mg (0.25 mL), 78 mg (0.5 mL), 117 mg (0.75 mL), 156 mg (1.0 mL), and 234 mg (1.5 mL). The drug product hydrolyzes to the active moiety, paliperidone, resulting in dose strengths of 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg of paliperidone, respectively. The inactive ingredients are polysorbate 20 (12 mg/mL), polyethylene glycol 4000 (30 mg/mL), citric acid monohydrate (5 mg/mL), disodium hydrogen phosphate anhydrous, sodium dihydrogen phosphate monohydrate, sodium hydroxide, and water for injection.

INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> is provided in a prefilled syringe (cyclic-olefin-copolymer) with a plunger stopper and tip cap (bromobutyl rubber). The kit also contains 2 safety needles (a 1 ½-inch 22 gauge safety needle and a 1-inch 23 gauge safety needle).

## **12 CLINICAL PHARMACOLOGY**

### **12.1 Mechanism of Action**

Paliperidone palmitate is hydrolyzed to paliperidone [*see Clinical Pharmacology (12.3)*]. Paliperidone is the major active metabolite of risperidone. The mechanism of action of paliperidone is unknown. However, it has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D<sub>2</sub>) and serotonin Type 2 (5HT<sub>2A</sub>) receptor antagonism.

### **12.2 Pharmacodynamics**

Paliperidone is a centrally active dopamine Type 2 (D<sub>2</sub>) receptor antagonist and a serotonin Type 2 (5HT<sub>2A</sub>) receptor antagonist. Paliperidone is also active as an antagonist at  $\alpha_1$  and  $\alpha_2$  adrenergic receptors and H<sub>1</sub> histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone has no affinity for cholinergic muscarinic or  $\beta_1$ - and  $\beta_2$ -adrenergic receptors. The pharmacological activity of the (+)- and (-)- paliperidone enantiomers is qualitatively and quantitatively similar *in vitro*.

### **12.3 Pharmacokinetics**

#### **Absorption and Distribution**

Due to its extremely low water solubility, paliperidone palmitate dissolves slowly after intramuscular injection before being hydrolyzed to paliperidone and absorbed into the systemic circulation. Following a single intramuscular dose, the plasma concentrations of paliperidone gradually rise to reach maximum plasma concentrations at a median T<sub>max</sub> of 13 days. The release of the drug starts as early as day 1 and lasts for as long as 126 days.

Following intramuscular injection of single doses (39 mg - 234 mg) in the deltoid muscle, on average, a 28% higher C<sub>max</sub> was observed compared with injection in the gluteal muscle. The two initial deltoid intramuscular injections of 234 mg on day 1 and 156 mg on day 8 help attain therapeutic concentrations rapidly. The release profile and dosing regimen of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> results in sustained therapeutic concentrations. The AUC of paliperidone following INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> administration was dose-proportional over a 39 mg-234 mg dose range, and less than dose-proportional for C<sub>max</sub> for doses exceeding 78 mg. The mean steady-state peak:trough ratio for an INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> dose of 156 mg was 1.8 following gluteal administration and 2.2 following deltoid administration.

Following administration of paliperidone palmitate the (+) and (-) enantiomers of paliperidone interconvert, reaching an AUC (+) to (-) ratio of approximately 1.6–1.8.

Based on a population analysis, the apparent volume of distribution of paliperidone is 391 L. The plasma protein binding of racemic paliperidone is 74%.

### Metabolism and Elimination

In a study with oral immediate-release <sup>14</sup>C-paliperidone, one week following administration of a single oral dose of 1 mg immediate-release <sup>14</sup>C-paliperidone, 59% of the dose was excreted unchanged into urine, indicating that paliperidone is not extensively metabolized in the liver. Approximately 80% of the administered radioactivity was recovered in urine and 11% in the feces. Four metabolic pathways have been identified *in vivo*, none of which accounted for more than 10% of the dose: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission. Although *in vitro* studies suggested a role for CYP2D6 and CYP3A4 in the metabolism of paliperidone, there is no evidence *in vivo* that these isozymes play a significant role in the metabolism of paliperidone. Population pharmacokinetics analyses indicated no discernible difference on the apparent clearance of paliperidone after administration of oral paliperidone between extensive metabolizers and poor metabolizers of CYP2D6 substrates.

The median apparent half-life of paliperidone following INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> single-dose administration over the dose range of 39 mg - 234 mg ranged from 25 days - 49 days.

### Long-Acting Paliperidone Palmitate Injection versus Oral Extended-Release Paliperidone

INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> is designed to deliver paliperidone over a monthly period while extended-release oral paliperidone is administered on a daily basis. The initiation regimen for INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> (234 mg/156 mg in the deltoid muscle on Day 1/Day 8) was designed to rapidly attain steady-state paliperidone concentrations when initiating therapy without the use of oral supplementation.

In general, overall initiation plasma levels with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> were within the exposure range observed with 6-12 mg extended-release oral paliperidone. The use of the INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> initiation regimen allowed patients to stay in this exposure window of 6-12 mg extended-release oral paliperidone even on trough pre-dose days (Day 8 and Day 36). The intersubject variability for paliperidone pharmacokinetics following delivery from INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> was lower relative to the variability determined from extended-release oral paliperidone tablets. Because of the difference in median pharmacokinetic profiles between the two products, caution should be exercised when making a direct comparison of their pharmacokinetic properties.

## Drug Interaction Studies

### ***Potential for INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> to Affect Other Drugs***

*In vitro* studies in human liver microsomes demonstrated that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner. Paliperidone is also not expected to have enzyme inducing properties.

Paliperidone is a weak inhibitor of P-glycoprotein (P-gp) at high concentrations. No *in vivo* data are available, and the clinical relevance is unknown.

In a drug interaction study, co-administration of oral paliperidone extended-release tablets (12 mg once daily for 5 days) with divalproex sodium extended-release tablets (500 mg to 2000 mg once daily) did not affect the steady-state pharmacokinetics ( $AUC_{24h}$  and  $C_{max,ss}$ ) of valproate in 13 patients stabilized on valproate. In a clinical study, subjects on stable doses of valproate had comparable valproate average plasma concentrations when oral paliperidone extended-release tablets 3-15 mg/day was added to their existing valproate treatment [see *Drug Interactions (7.1)*].

### ***Potential for Other Drugs to Affect INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>***

While *in vitro* studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, *in vivo* studies did not demonstrate decreased elimination by these isozymes; they contribute to only a small fraction of total body clearance. *In vitro* studies demonstrated that paliperidone is a P-gp substrate [see *Drug Interactions (7.2)*].

Co-administration of oral paliperidone extended-release 6 mg once daily with carbamazepine, a strong inducer of both CYP3A4 and P-gp, at 200 mg twice daily caused a decrease of approximately 37% in the mean steady-state  $C_{max}$  and AUC of paliperidone. This decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone. A minor decrease in the amount of drug excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration [see *Drug Interactions (7.2)*].

Co-administration of a single dose of oral paliperidone extended-release 12 mg tablet with divalproex sodium extended-release tablets (two 500 mg tablets once daily at steady-state) resulted in an increase of approximately 50% in the  $C_{max}$  and AUC of paliperidone. Although this interaction has not been studied with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>, a clinically significant interaction would not be expected between divalproex sodium and INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> intramuscular injection [see *Drug Interactions (7.2)*].

Paliperidone is metabolized to a limited extent by CYP2D6. In an interaction study in healthy subjects in which a single 3 mg dose of oral paliperidone extended-release was administered concomitantly with 20 mg per day of paroxetine (a potent CYP2D6 inhibitor), paliperidone exposures were on average 16% (90% CI: 4, 30) higher in CYP2D6 extensive metabolizers. Higher doses of paroxetine have not been studied. The clinical relevance is unknown.

## Specific Populations

### *Renal Impairment*

INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> has not been systematically studied in patients with renal impairment. Based on a limited number of observations with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> in subjects with mild renal impairment and pharmacokinetic simulations, the dose of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> should be reduced in patients with mild renal impairment; INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> is not recommended in patients with moderate or severe renal impairment. Although INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> was not studied in patients with moderate or severe renal impairment, the disposition of a single oral dose paliperidone 3 mg extended-release tablet was studied in subjects with varying degrees of renal function. Elimination of paliperidone decreased with decreasing estimated creatinine clearance. Total clearance of paliperidone was reduced in subjects with impaired renal function by 32% on average in mild (CrCl = 50 mL/min to < 80 mL/min), 64% in moderate (CrCl = 30 mL/min to < 50 mL/min), and 71% in severe (CrCl = 10 mL/min to < 30 mL/min) renal impairment, corresponding to an average increase in exposure (AUC<sub>inf</sub>) of 1.5 fold, 2.6 fold, and 4.8 fold, respectively, compared to healthy subjects [*see Dosage and Administration (2.5) and Use in Specific Populations (8.6)*].

### *Hepatic Impairment*

INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> has not been studied in patients with hepatic impairment. Based on a study with oral paliperidone in subjects with moderate hepatic impairment (Child-Pugh class B), no dose adjustment is required in patients with mild or moderate hepatic impairment. In the study with oral paliperidone in subjects with moderate hepatic impairment (Child-Pugh class B), the plasma concentrations of free paliperidone were similar to those of healthy subjects, although total paliperidone exposure decreased because of a decrease in protein binding. Paliperidone has not been studied in patients with severe hepatic impairment [*see Use in Specific Populations (8.7)*].

### *Elderly*

No dosage adjustment is recommended based on age alone. However, dose adjustment may be required because of age-related decreases in creatinine clearance [*see Renal Impairment above and Dosage and Administration (2.5)*].

### ***Race***

No dosage adjustment is recommended based on race. No differences in pharmacokinetics were observed between Japanese and Caucasians.

### ***Gender***

No dosage adjustment is recommended based on gender, although slower absorption was observed in females in a population pharmacokinetic analysis.

### ***Smoking***

No dosage adjustment is recommended based on smoking status. Based on *in vitro* studies utilizing human liver enzymes, paliperidone is not a substrate for CYP1A2; smoking should, therefore, not have an effect on the pharmacokinetics of paliperidone.

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

#### **Carcinogenesis**

The carcinogenic potential of intramuscularly injected paliperidone palmitate was assessed in rats. There was an increase in mammary gland adenocarcinomas in female rats at 16, 47, and 94 mg/kg/month, which is 0.6, 2, and 4 times, respectively, the maximum recommended human 234 mg dose of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> on a mg/m<sup>2</sup> body surface area basis. A no-effect dose was not established. Male rats showed an increase in mammary gland adenomas, fibroadenomas, and carcinomas at 47 mg and 94 mg/kg/month. A carcinogenicity study in mice has not been conducted with paliperidone palmitate.

Carcinogenicity studies of risperidone, which is extensively converted to paliperidone in rats, mice, and humans, were conducted in Swiss albino mice and Wistar rats. Risperidone was administered in the diet at daily doses of 0.63, 2.5, and 10 mg/kg for 18 months to mice and for 25 months to rats. A maximum tolerated dose was not achieved in male mice. There were statistically significant increases in pituitary gland adenomas, endocrine pancreas adenomas, and mammary gland adenocarcinomas. The no-effect dose for these tumors was less than or equal to the maximum recommended human dose of risperidone on a mg/m<sup>2</sup> body surface area basis (see RISPERDAL<sup>®</sup> package insert). An increase in mammary, pituitary, and endocrine pancreas neoplasms has been found in rodents after chronic administration of other antipsychotic drugs and is considered to be mediated by prolonged dopamine D<sub>2</sub>-receptor antagonism and hyperprolactinemia. The relevance of these tumor findings in rodents in terms of human risk is unknown [see *Warnings and Precautions (5.9)*].

#### **Mutagenesis**

Paliperidone palmitate showed no genotoxic potential in the Ames reverse mutation test or the

mouse lymphoma assay. No evidence of genotoxic potential for paliperidone was found in the Ames reverse mutation test, the mouse lymphoma assay, or the *in vivo* rat micronucleus test.

### Impairment of Fertility

Fertility studies of paliperidone palmitate have not been performed.

In a study of fertility conducted with orally administered paliperidone, the percentage of treated female rats that became pregnant was not affected at doses of paliperidone of up to 2.5 mg/kg/day. However, pre- and post-implantation loss were increased, and the number of live embryos was slightly decreased, at 2.5 mg/kg, a dose that also caused slight maternal toxicity. These parameters were not affected at a dose of 0.63 mg/kg, which is half of the maximum recommended human dose (12 mg/day) of orally administered paliperidone (INVEGA<sup>®</sup>) on a mg/m<sup>2</sup> body surface area basis.

The fertility of male rats was not affected at oral doses of paliperidone of up to 2.5 mg/kg/day, although sperm count and sperm viability studies were not conducted with paliperidone. In a subchronic study in Beagle dogs with risperidone, which is extensively converted to paliperidone in dogs and humans, all doses tested (0.31 mg/kg - 5.0 mg/kg) resulted in decreases in serum testosterone and in sperm motility and concentration. Serum testosterone and sperm parameters partially recovered, but remained decreased after the last observation (two months after treatment was discontinued).

## 14 CLINICAL STUDIES

The efficacy of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> was established in the following adequate and well-controlled trials:

- Four short-term, fixed-dose trials and one maintenance trial in adults with schizophrenia as monotherapy [*see Clinical Studies (14.1)*]
- One long-term, flexible-dose maintenance trial in adults with schizoaffective disorder as monotherapy or as adjunctive therapy to a mood stabilizer or antidepressant [*see Clinical Studies (14.2)*]

### 14.1 Schizophrenia

#### Short-Term Monotherapy (Studies 1, 2, 3, 4)

The efficacy of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> in the acute treatment of schizophrenia was evaluated in four short-term (one 9-week and three 13-week) double-blind, randomized, placebo-controlled, fixed-dose studies of acutely relapsed adult inpatients who met DSM-IV criteria for schizophrenia. The fixed doses of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> in these studies were given on days

1, 8, and 36 in the 9-week study, and additionally on day 64 of the 13-week studies, i.e., at a weekly interval for the initial two doses and then every 4 weeks for maintenance.

Efficacy was evaluated using the total score on the Positive and Negative Syndrome Scale (PANSS). The PANSS is a 30 item scale that measures positive symptoms of schizophrenia (7 items), negative symptoms of schizophrenia (7 items), and general psychopathology (16 items), each rated on a scale of 1 (absent) to 7 (extreme); total PANSS scores range from 30 to 210.

In Study 1 (PSY-3007), a 13-week study (n=636) comparing three fixed doses of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> (initial deltoid injection of 234 mg followed by 3 gluteal or deltoid doses of either 39 mg/4 weeks, 156 mg/4 weeks or 234 mg/4 weeks) to placebo, all three doses of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> were superior to placebo in improving the PANSS total score.

In Study 2 (PSY-3003), another 13-week study (n=349) comparing three fixed doses of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> (78 mg/4 weeks, 156 mg/4 weeks, and 234 mg/4 weeks) to placebo, only 156 mg/4 weeks of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> was superior to placebo in improving the PANSS total score.

In Study 3 (PSY-3004), a third 13-week study (n=513) comparing three fixed doses of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> (39 mg/4 weeks, 78 mg/4 weeks, and 156 mg/4 weeks) to placebo, all three doses of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> were superior to placebo in improving the PANSS total score.

In Study 4 (SCH-201), the 9-week study (n=197) comparing two fixed doses of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> (78 mg/4 weeks and 156 mg/4 weeks) to placebo, both doses of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> were superior to placebo in improving PANSS total score.

A summary of the mean baseline PANSS scores along with the mean changes from baseline in the four short-term acute schizophrenia studies are provided in Table 13.

**Table 13. Schizophrenia Short-term Studies**

| Study Number               | Treatment Group                                             | Primary Efficacy Measure: PANSS Total Score |                                   |                                                     |
|----------------------------|-------------------------------------------------------------|---------------------------------------------|-----------------------------------|-----------------------------------------------------|
|                            |                                                             | Mean Baseline Score (SD)                    | LS Mean Change from Baseline (SE) | Placebo-subtracted Difference <sup>a</sup> (95% CI) |
| <b>Study 1</b>             | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup> (39 mg/4 weeks)*  | 86.9 (11.99)                                | -11.2 (1.69)                      | -5.1 (-9.01, -1.10)                                 |
|                            | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup> (156 mg/4 weeks)* | 86.2 (10.77)                                | -14.8 (1.68)                      | -8.7 (-12.62, -4.78)                                |
|                            | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup> (234 mg/4 weeks)* | 88.4 (11.70)                                | -15.9 (1.70)                      | -9.8 (-13.71, -5.85)                                |
|                            | Placebo                                                     | 86.8 (10.31)                                | -6.1 (1.69)                       | --                                                  |
| <b>Study 2<sup>b</sup></b> | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup> (78 mg/4 weeks)   | 89.9 (10.78)                                | -6.9 (2.50)                       | -3.5 (-8.73, 1.77)                                  |
|                            | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup> (156 mg/4 weeks)* | 90.1 (11.66)                                | -10.4 (2.47)                      | -6.9 (-12.12, -1.68)                                |
|                            | Placebo                                                     | 92.4 (12.55)                                | -3.5 (2.15)                       | --                                                  |
| <b>Study 3</b>             | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup> (39 mg/4 weeks)*  | 90.7 (12.25)                                | -19.8 (2.19)                      | -6.6 (-11.40, -1.73)                                |
|                            | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup> (78 mg/4 weeks)*  | 91.2 (12.02)                                | -19.2 (2.19)                      | -5.9 (-10.76, -1.07)                                |
|                            | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup> (156 mg/4 weeks)* | 90.8 (11.70)                                | -22.5 (2.18)                      | -9.2 (-14.07, -4.43)                                |
|                            | Placebo                                                     | 90.7 (12.22)                                | -13.3 (2.21)                      | --                                                  |
| <b>Study 4</b>             | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup> (78 mg/4 weeks)*  | 88.0 (12.39)                                | -4.6 (2.43)                       | -11.2 (-16.85, -5.57)                               |
|                            | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup> (156 mg/4 weeks)* | 85.2 (11.09)                                | -7.4 (2.45)                       | -14.0 (-19.51, -8.58)                               |
|                            | Placebo                                                     | 87.8 (13.90)                                | 6.6 (2.45)                        | --                                                  |

SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: unadjusted confidence interval.

<sup>a</sup> Difference (drug minus placebo) in least-squares mean change from baseline.

<sup>b</sup> Because an insufficient number of subjects received the 234 mg/4 weeks dose, results from this group are not included.


\* p<0.05 (Doses statistically significantly superior to placebo).

### Maintenance Monotherapy Treatment (Study 5: PSY-3001)

The efficacy of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> in maintaining symptomatic control in schizophrenia was established in a longer-term double-blind, placebo-controlled, flexible-dose study involving adult subjects who met DSM-IV criteria for schizophrenia. This study included a minimum 12-week, fixed-dose stabilization phase, and a randomized, placebo-controlled phase to observe for relapse. During the double-blind phase, patients were randomized to either the same dose of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> they received during the stabilization phase, i.e., 39 mg, 78 mg, or 156 mg administered every 4 weeks, or to placebo. A total of 410 stabilized patients were randomized to either INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> or to placebo until they experienced a relapse of schizophrenia symptoms. Relapse was pre-defined as time to first emergence of one or more of the following: psychiatric hospitalization,  $\geq 25\%$  increase (if the baseline score was  $> 40$ ) or a 10-point increase (if the baseline score was  $\leq 40$ ) in total PANSS score on two consecutive

assessments, deliberate self-injury, violent behavior, suicidal/homicidal ideation, or a score of  $\geq 5$  (if the maximum baseline score was  $\leq 3$ ) or  $\geq 6$  (if the maximum baseline score was 4) on two consecutive assessments of the specific PANSS items. The primary efficacy variable was time to relapse. A pre-planned interim analysis showed a statistically significantly longer time to relapse in patients treated with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> compared to placebo, and the study was stopped early because maintenance of efficacy was demonstrated. Thirty-four percent (34%) of subjects in the placebo group and 10% of subjects in the INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> group experienced a relapse event. There was a statistically significant difference between the treatment groups in favor of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>. A Kaplan-Meier plot of time to relapse by treatment group is shown in Figure 1. The time to relapse for subjects in the placebo group was statistically significantly shorter than for the INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> group. An examination of population subgroups did not reveal any clinically significant differences in responsiveness on the basis of gender, age, or race.

**Figure 1:** Kaplan-Meier Plot of Cumulative Proportion of Subjects with Relapse Over Time (Schizophrenia Study 5)



## 14.2 Schizoaffective Disorder

### Maintenance Treatment – Monotherapy and as Adjunct to Mood Stabilizer or Antidepressant (SAff Study 1: SCA-3004)

The efficacy of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> in maintaining symptom control in schizoaffective disorder was established in a long-term double-blind, placebo-controlled, flexible-dose randomized-withdrawal study designed to delay relapse in adult subjects who met DSM-IV criteria for schizoaffective disorder, as confirmed by the Structured Clinical Interview for DSM-IV Disorders. The population included subjects with schizoaffective bipolar and depressive types. Subjects received INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> either as monotherapy or as an adjunct to stable doses of antidepressant or mood stabilizers.

This study included a 13-week, open-label, flexible-dose (INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> 78 mg, 117 mg, 156 mg, or 234 mg) lead-in period which enrolled a total of 667 subjects who had 1) acute exacerbation of psychotic symptoms; 2) score  $\geq 4$  on  $\geq 3$  PANSS items of delusions, conceptual disorganization, hallucinatory behavior, excitement, suspiciousness/persecution, hostility, uncooperativeness, tension, and poor impulse control; and 3) prominent mood symptoms  $\geq 16$  on the Young Mania Rating Scale (YMRS) and/or the Hamilton Rating Scale for Depression, 21-item version (HAM-D-21). Subjects were 19 to 66 years old (mean 39.5 years) and 53.5% were male. The mean scores at open-label enrollment of PANSS total was 85.8 (range 42 to 128), HAM-D-21 was 20.4 (range 3 to 43), YMRS was 18.6 (range 0 to 50), and CGI-S-SCA was 4.4 (range 2 to 6).

After the 13-week open-label flexible-dose INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> treatment, 432 subjects met stabilization criteria (PANSS total score  $\leq 70$ , YMRS  $\leq 12$ , and HAM-D-21  $\leq 12$ ) and continued into the 12-week open-label fixed-dose stabilization period.

A total of 334 subjects who met stabilization criteria for 12 consecutive weeks were randomized (1:1) to continue the same dose of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> or to placebo in the 15-month, double-blind, maintenance period. For the 164 subjects who were randomized to INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>, dose distribution was 78 mg (4.9%), 117 mg (9.8%), 156 mg (47.0%), and 234 mg (38.4%). The primary efficacy variable was time to relapse. Relapse was defined as the first occurrence of one or more of the following: 1) psychiatric hospitalization; 2) intervention employed to avert hospitalization; 3) clinically significant self-injury, suicidal or homicidal ideation or violent behavior; 4) a score of  $\geq 6$  (if the score was  $\leq 4$  at randomization) of any of the individual PANSS items: delusions, conceptual disorganization, hallucinatory behavior, excitement, suspiciousness/persecution, hostility, uncooperativeness, or poor impulse control; 5) on two consecutive assessments within 7 days:  $\geq 25\%$  increase (if the score at randomization was  $> 45$ ) or  $\geq 10$ -point increase (if the score at randomization was  $\leq 45$ ) in total PANSS score; a score

of  $\geq 5$  (if the score was  $\leq 3$  at randomization) of any of the individual PANSS items: delusions, conceptual disorganization, hallucinatory behavior, excitement, suspiciousness/persecution, hostility, uncooperativeness, or poor impulse control; an increase of  $\geq 2$  points (if the score was 1 [not ill] to 3 [mildly ill] at randomization) or increase of  $\geq 1$  point (if the score was  $\geq 4$  [moderately ill or worse] at randomization) in CGI-S-SCA overall score.

There was a statistically significant difference in time to relapse between the treatment groups in favor of INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>. A Kaplan-Meier plot of time to relapse by treatment group is shown in Figure 2.

**Figure 2:** Kaplan-Meier Plot of Cumulative Proportion of Subjects with Relapse Over Time (Saff Study 1)




Table 14 summarizes the number of subjects with relapse in the overall population, by subgroup (monotherapy vs. adjunctive therapy), and by symptom type at the first occurrence of relapse.

**Table 14. Summary of Relapse Rates (SAff Study 1).**

|                                                                 | Number (Percent) of Subjects Who Relapsed |                                                    |
|-----------------------------------------------------------------|-------------------------------------------|----------------------------------------------------|
|                                                                 | Placebo<br>N=170                          | INVEGA <sup>®</sup> SUSTENNA <sup>®</sup><br>N=164 |
| <b>All Subjects</b>                                             | 57 (33.5%)                                | 25 (15.2%)                                         |
| <b>Monotherapy subset</b>                                       | N=73<br>24 (32.9%)                        | N=78<br>9 (11.5%)                                  |
| <b>Adjunct to Antidepressants or<br/>Mood Stabilizer subset</b> | N=97<br>33 (34.0%)                        | N=86<br>16 (18.6%)                                 |
| <b>Psychotic Symptoms<sup>a</sup></b>                           | 53 (31.2%)                                | 21 (12.8%)                                         |
| <b>Mood Symptoms<sup>b</sup></b>                                |                                           |                                                    |
| <b>Any Mood Symptoms</b>                                        | 48 (28.2%)                                | 18 (11.0%)                                         |
| <b>Manic</b>                                                    | 16 (9.4%)                                 | 5 (3.0%)                                           |
| <b>Depressive</b>                                               | 23 (13.5%)                                | 8 (4.9%)                                           |
| <b>Mixed</b>                                                    | 9 (5.3%)                                  | 5 (3.0%)                                           |

<sup>a</sup> 8 subjects experienced a relapse without psychotic symptoms.

<sup>b</sup> 16 subjects experienced a relapse without any mood symptoms.

## 16 HOW SUPPLIED/STORAGE AND HANDLING

INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> is available as a white to off-white sterile aqueous extended-release suspension for intramuscular injection in dose strengths of 39 mg, 78 mg, 117 mg, 156 mg, and 234 mg paliperidone palmitate. The kit contains a prefilled syringe and 2 safety needles (a 1 ½-inch 22 gauge safety needle and a 1-inch 23 gauge safety needle).

39 mg paliperidone palmitate kit (NDC 50458-560-01)

78 mg paliperidone palmitate kit (NDC 50458-561-01)

117 mg paliperidone palmitate kit (NDC 50458-562-01)

156 mg paliperidone palmitate kit (NDC 50458-563-01)

234 mg paliperidone palmitate kit (NDC 50458-564-01)

### Storage and Handling

Store at room temperature (25°C, 77°F); excursions between 15°C and 30°C (between 59°F and 86°F) are permitted.

## **17 PATIENT COUNSELING INFORMATION**

See FDA-approved patient labeling (Patient Information)

Physicians are advised to discuss the following issues with patients for whom they prescribe INVEGA<sup>®</sup> SUSTENNA<sup>®</sup>.

### **Orthostatic Hypotension**

Patients should be advised that there is risk of orthostatic hypotension, particularly at the time of initiating treatment, re-initiating treatment, or increasing the dose [*see Warnings and Precautions (5.7)*].

### **Interference with Cognitive and Motor Performance**

Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> therapy does not affect them adversely, as INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> has the potential to impair judgment, thinking, or motor skills [*see Warnings and Precautions (5.10)*].

### **Pregnancy**

Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> [*see Use in Specific Populations (8.1)*].

### **Nursing**

Inform patients and caregivers that INVEGA<sup>®</sup> SUSTENNA<sup>®</sup> is present in human breast milk; there is a potential for serious adverse reactions in nursing infants. Advise patients that the decision whether to discontinue nursing or to discontinue the drug should take into account the importance of the drug to the patient [*see Use in Specific Populations (8.3)*].

### **Concomitant Medication**

Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, as there is a potential for interactions [*see Drug Interactions (7.1, 7.2)*].

### **Heat Exposure and Dehydration**

Patients should be advised regarding appropriate care in avoiding overheating and dehydration [*see Warnings and Precautions (5.14)*].

INVEGA® SUSTENNA® (paliperidone palmitate) Extended-Release Injectable Suspension

Product of Ireland

Manufactured by:  
Janssen Pharmaceutica N.V.  
Beerse, Belgium

Manufactured for:  
Janssen Pharmaceuticals, Inc.  
Titusville, NJ 08560

© Janssen Pharmaceuticals, Inc. 2009

**PATIENT INFORMATION**  
**INVEGA® SUSTENNA® (In-VEY-guh Suss-TEN-uh)**  
**(paliperidone palmitate)**  
**Extended-Release Injectable Suspension**

Read this Patient Information carefully before you receive INVEGA SUSTENNA and each time you receive it. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

**What is the most important information I should know about INVEGA SUSTENNA?**

**INVEGA SUSTENNA can cause serious side effects, including:**

- **Increased risk of death in elderly people who are confused, have memory loss and have lost touch with reality (dementia-related psychosis).** INVEGA SUSTENNA is not for treating dementia-related psychosis.

**What is INVEGA SUSTENNA?**

INVEGA SUSTENNA is a prescription medicine given by injection by a health care professional and used to treat:

- schizophrenia
- schizoaffective disorder either alone or with other medicines such as mood stabilizers or antidepressants

It is not known if INVEGA SUSTENNA is safe and effective in children under 18 years of age.

**Who should not receive INVEGA SUSTENNA?**

**Do not receive INVEGA SUSTENNA if you:**

- are allergic to paliperidone, risperidone, or any of the ingredients in INVEGA SUSTENNA. See the end of this Patient Information leaflet for a complete list of ingredients in INVEGA SUSTENNA.

**What should I tell my healthcare provider before receiving INVEGA SUSTENNA?**

Before you receive INVEGA SUSTENNA, tell your healthcare provider about all your medical conditions, including if you:

- have had Neuroleptic Malignant Syndrome (NMS)
- have or have had heart problems, including a heart attack, heart failure, abnormal heart rhythm, or long QT syndrome
- have or have had low levels of potassium or magnesium in your blood
- have or have had uncontrolled movements of your tongue, face, mouth, or jaw (tardive dyskinesia)
- have or have had kidney or liver problems
- have diabetes or have a family history of diabetes
- have had a low white blood cell count

- have had problems with dizziness or fainting or are being treated for high blood pressure
- have or have had seizures or epilepsy
- have any other medical conditions
- are pregnant or plan to become pregnant. It is not known if INVEGA SUSTENNA will harm your unborn baby.
- are breastfeeding or plan to breastfeed. INVEGA SUSTENNA can pass into your breast milk and may harm your baby. You and your healthcare provider should decide if you will receive INVEGA SUSTENNA or breastfeed. You should not do both.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Know the medicines you take. Keep a list of them to show to your healthcare provider or pharmacist when you get a new medicine.

### **How will I receive INVEGA SUSTENNA?**

- Take INVEGA SUSTENNA exactly as your healthcare provider tells you to.
- Your healthcare provider will tell you how much INVEGA SUSTENNA you will receive and when you will receive it.
- INVEGA SUSTENNA is given as an injection by your healthcare provider into the muscle (intramuscularly) of your arm or your buttocks.
- When you receive your first dose of INVEGA SUSTENNA you will need to get a second dose 1 week later. After that you will only need to get a dose 1 time a month.

### **What should I avoid while receiving INVEGA SUSTENNA?**

- INVEGA SUSTENNA may affect your ability to make decisions, think clearly, or react quickly. **Do not** drive, operate heavy machinery, or do other dangerous activities until you know how INVEGA SUSTENNA affects you.
- Avoid getting overheated or dehydrated.

### **What are the possible side effects of INVEGA SUSTENNA?**

**INVEGA SUSTENNA may cause serious side effects, including:**

- See **“What is the most important information I should know about INVEGA SUSTENNA?”**
- **stroke in elderly people (cerebrovascular problems) that can lead to death**
- **Neuroleptic Malignant Syndrome (NMS).** NMS is a rare but very serious problem that can happen in people who receive INVEGA SUSTENNA. NMS can cause death and must be treated in a hospital. Call your healthcare provider right away if you become severely ill and have any of these symptoms:
  - high fever
  - severe muscle stiffness
  - confusion
  - loss of consciousness
  - changes in your breathing, heartbeat and blood pressure

- **problems with your heartbeat.** These heart problems can cause death. Call your healthcare provider right away if you have any of these symptoms:
  - passing out or feeling like you will pass out
  - dizziness
  - feeling as if your heart is pounding or missing beats
- **uncontrolled movements of your tongue, face, mouth, or jaw (tardive dyskinesia)**
- **metabolic changes.** Metabolic changes may include high blood sugar (hyperglycemia), diabetes mellitus and changes in the fat levels in your blood (dyslipidemia), and weight gain.
- **low blood pressure and fainting**
- **changes in your blood cell counts**
- **high level of prolactin in your blood (hyperprolactemia).** INVEGA SUSTENNA may cause a rise in the blood levels of a hormone called prolactin (hyperprolactemia) that may cause side effects including missed menstrual periods, leakage of milk from the breasts, development of breasts in men, or problems with erection
- **problems thinking clearly and moving your body**
- **seizures**
- **difficulty swallowing that can cause food or liquid to get into your lungs**
- **prolonged or painful erection lasting more than 4 hours.** Call your healthcare provider or go to your nearest emergency room right away if you have an erection that lasts more than 4 hours.
- **problems with control of your body temperature especially when you exercise a lot or spend time doing things that make you warm. It is important for you to drink water to avoid dehydration.**

**The most common side effects of INVEGA SUSTENNA include:**

- injection site reactions
- sleepiness or drowsiness
- dizziness
- feeling of inner restlessness or needing to be constantly moving
- abnormal muscle movements, including tremor (shaking), shuffling, uncontrolled involuntary movements, and abnormal movements of your eyes

Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of INVEGA SUSTENNA. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

**General information about the safe and effective use of INVEGA SUSTENNA.**

This Patient Information leaflet summarizes the most important information about INVEGA SUSTENNA. If you would like more information, talk with your healthcare provider.

You can ask your healthcare provider or pharmacist for more information that is written for healthcare professionals. For more information, go to [www.invegasustenna.com](http://www.invegasustenna.com) or call 1-800-526-7736.

**What are the ingredients in INVEGA SUSTENNA?**

**Active ingredient:** paliperidone palmitate

**Inactive ingredients:** polysorbate 20, polyethylene glycol 4000, citric acid monohydrate, disodium hydrogen phosphate anhydrous, sodium dihydrogen phosphate monohydrate, sodium hydroxide, and water for injection

Manufactured by: Janssen Pharmaceuticals, Inc. Titusville, NJ 08560, Janssen Pharmaceuticals, Inc. 2009

This Patient Information has been approved by the U.S. Food and Drug Administration

Revised: November 2014